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What this dissertation is about 
Growing and aging populations implies increasing numbers of people with cognitive impairment and 
dementia. Alzheimer’s disease (AD) is the most common dementia type, 60-80 % of those with 
dementia having AD [1]. AD consists of around 75 % sporadic late-onset AD (LOAD), 15-25 % familial 
LOAD and around 5 % early-onset AD (EOAD) (figure 1) [2-5]. EOAD comprises familial EOAD (<1 %) 
and sporadic EOAD (4-5 %) [6]. Age of onset is considered to be before the age of 60-65 years for 
EOAD and after the age of 60-65 years for LOAD [4,6-8]. After many years of preclinical disease 
activity, perhaps several decades, AD eventually brings about subjective memory complaints (SMC) 
and mild cognitive impairment (MCI) until manifesting itself as dementia [9].  
Figure 1. Subclassification of AD 
 
AD is a neurodegenerative disease with unclear etiology and pathophysiology. High age is the major 
known risk factor, secondly being a carrier of the ApoE ε4 allele or being a member of a family with 
aggregation of AD [4].  
There are many hypotheses about the pathophysiology of AD, the amyloid hypothesis being 
predominant since 1991 [8,10]. The amyloid hypothesis has not yet been proven, but also remains to 
be disproven [11]. An imbalance between production and clearance of Aβ42 and related peptides 
leads to Aβ accumulation in the brain. This is an early or initiating factor of AD [8,12]. In dominantly 
inherited AD, missense mutations in the amyloid precursor protein (APP), presinilin 1 and presinilin 2 
genes cause overproduction of Aβ42. Dominantly inherited AD – familial EOAD – is rare, and 
constitutes less than 1 % of AD cases. In the most prevalent forms of AD, sporadic and familial LOAD, 
there is failure of Aβ clearance mechanisms [8]. 
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Neuronal amyloid precursor protein (APP), an integral membrane protein consisting of 695 amino 
acids, is particularly expressed in the synapses. APP has been implicated as a regulator of synaptic 
formation and repair, and of anterograde neuronal transport [12]. In dominantly inherited AD, 
cleavage of APP first at position 1 by β secretase (amyloidogenic pathway) and then at position 42 by 
ϒ-secretase, leads to relative overproduction of the long more insoluble and toxic peptide Aβ(1-42), 
commonly referred to as Aβ42 (figure 2) [12]. Compared with shorter Aβ peptides, including Aβ40 
which is most common, Aβ42 enhances aggregation propensity, promoting accelerated formation of 
extraneuronal small Aβ oligomers, protofibrils, fibrils and amyloid plaques [2,12,13]. The oligomeric 
form of Aβ is considered to be most synaptotoxic. The deposited Aβ has a high content of β-pleated 
sheet secondary structure. In the non-amyloidogenic pathway, APP is initially cleaved by α-secretase 
and subsequently by ϒ-secretase. 
Figure 2. APP proteolytic pathways 
 
Figure: Chen et al., Acta Pharmalogica Sinica, 2017: 1205-1235 (permission granted from publisher) 
There are several different types of amyloid plaques [14]. The amyloid plaque consists of an Aβ core 
that to varying extents is surrounded by axonal and dendritic processes, Aβ fibrils, glial cell processes 
and microglial cells. Amyloid plaques are the end result of a process of Aβ oligomerisation, fibril 
formation, aggregation and precipitation, occurring in several stages, each stage potentially having a 
different impact on neurons in the vicinity [4].  
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According to the amyloid cascade hypothesis, Aβ-oligomers and Aβ-peptides promote 
hyperphosphorylation of intraneuronal tau protein (figure 3) [8]. Tau normally stabilizes and 
promotes the assembly of microtubules, facilitating the transport of intraneuronal products along 
the axon to synapses [4]. Hyperphosphorylated tau aggregates to form paired helical filament tau, 
causing disruption of the microtubules and aggregation into neurofibrillary tangles. This leads to 
dysfunctional neurons, synaptic loss and neuronal death. 
A causal relationship between extracellular deposits of Aβ-peptides and damage on intraneuronal 
tau protein has not, however, been shown [11]. Aβ and tau protein are the primary constituents of 




























Figure 3. The amyloid cascade hypothesis 
  
Figure: Dennis Selkoe and John Hardy, EMBO Molecular Medicine, Vol. 8, No. 6, 2016                   
(permission granted from publisher)  
The ApoE gene is located on chromosome 19, and has three alleles - ApoE ε2, ApoE ε3 and ApoE ε4. 
The ApoE ε4 allele was recognized as a risk factor for LOAD in 1993 [16]. Studies suggest that carriers 
of one ε4 allele (ε4 heterozygous) have two- to threefold increased odds of AD, whereas carriers of 
two ε4 alleles (ε4 homozygous) have 8-fold to 12-fold increased odds of AD compared with 
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noncarriers [17]. The ApoE ε4 allele may also impede cholinergic functions by reducing choline 
acetyltransferase activity and exacerbate the effects of cerebrovascular risk factors on cognitive 
function [18]. 
The ApoE gene is considered to be a susceptibility gene for LOAD. The ApoE ε4 allele is neither 
necessary nor sufficient for the development of LOAD, up to 50 % of AD patients not possessing the 
ApoE ε4 allele [19]. This indicates that the ApoE ε4 allele in combination with other genes and 
environmental risk factors can increase the risk of LOAD. 
Apolipoprotein E (ApoE) is strongly expressed in the brain and liver, and transports lipids, including 
cholesterol, throughout the cerebrospinal fluid (CSF) and plasma [18]. ApoE is synthesized by 
astrocytes and microglia and by neurons following injury. ApoE has a key function in supplying 
cholesterol for the development, maintenance and repair of myelin, neuronal membranes and 
synaptic connections. The three common isoforms of ApoE (ApoE ε2, ApoE ε3 and ApoE ε4) are 
coded for by the alleles, ε2, ε3 and ε4 respectively. ApoE ε3 is the most common isoform and ApoE 
ε2 the rarest. The isoforms differ profoundly in their ability to interact with Aβ. Increasing ε4 allele 
dose is associated with reduced clearance and increased accumulation of Aβ [18]. 
Vascular dementia (VaD) is the second most common dementia type. In Europe, 10-20 % of dementia 
cases have VaD [20]. Cerebral small vessel disease (CSVD) is the most prevalent cause of VaD 
[4,21,22]. Vascular cognitive impairment (VCI) refers to all forms of cognitive disorder associated 
with cerebrovascular disease [23]. VCI and VaD can occur in connection with cerebral strokes, while 
VCI due to CSVD usually manifests gradually, appearing as vascular mild cognitive impairment (vMCI) 













Figure 4. Gradual versus rapid development of VCI and VaD 
 
Figure: Pantoni et al., Cerebrovascular Diseases, 2009;27(suppl 1):191–196                                           
(permission granted from publisher)  
CSVD can appear as lacunes, white matter hyperintensities (WMH), microbleeds and increased 
perivascular spaces on MRI [22]. CSVD is associated with diffuse ischemic damage and cognitive 
dysfunction particularly in executive function and attention [25].                                                                                             
Cardiovascular risk factors are not only risk factors for CSVD and large vessel disease in VaD, but may 
also be risk factors for AD (figure 5) [26,27]. AD and CSVD often coexist in dementia and there 
appears to be a considerable overlap between AD and vascular disease. Dementia that is considered 
to be caused by both is termed mixed dementia [4]. It has been shown that appr. 34 % of patients 
with AD have mixed dementia [28]. ApoE leakage induced by CSVD has been associated with AD and 
accumulation of Aβ in perivascular astrocytes and transient induction of Aβ deposition [29]. Age 
related changes on cerebral arteries may impair drainage of soluble Aβ, which in turn leads to Aβ 








Figure 5. Determinants of VCI 
 
Figure: Dichgans and Leys, Circulation Research, 2017 Feb 3;120(3):573-591                                           
(permission granted from publisher) 
There are no biomarkers that can diagnose AD early, nor treatments that can curb, halt or cure AD. 
More knowledge about AD is therefore urgently required, the primary goal being to discover the 
etiologies and disease mechanisms underlying AD, to find treatments that can break the chain of 
events and halt the disease. Disease modifying treatments for AD clearly constitute inferior goals 
[30]. So far, different approaches aimed at inhibiting disease progression of AD with disease 
modifying treatments have failed to document beneficial effects [31,32]. The lack of good biomarkers 
for AD is an issue in this context, making it difficult to accurately quantify the effects of disease 
modifying treatments. 
LOAD has different causal factors and can have several different etiologies with similar presentation 
clinically, on brain imaging and histologically [33,34]. LOAD is considered to be a complex 
multifactorial disease with a number of genetic, epigenetic and environmental risk factors [35-39]. 
There are connections between cerebrovascular disease and LOAD, as well as differences between 
sporadic and familial LOAD [4,40,41]. 
In stroke free persons from a general population (papers I-III), we wanted to test associations 
between cardiovascular risk factors and cognitive function.                                                                                                                    
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Moreover, we wanted to test whether mild cognitive impairment (MCI) in persons with probable 
prodromal sporadic LOAD differs from MCI in persons with probable prodromal familial LOAD.  
Paper I was a cross-sectional case-control study of 103 cases and 58 controls. Fully automated 
magnetic resonance (MR) volumetry of cerebral structures was carried out on persons with MCI who 
came from families with aggregation of LOAD (these cases were considered to have probable 
prodromal familial LOAD), on persons with MCI from families without LOAD (these cases were 
considered to have probable prodromal sporadic LOAD) and on controls.                                                       
Volumetric measurements on persons with MCI and probable prodromal familial LOAD, and persons 
with MCI and probable prodromal sporadic LOAD were compared to controls and each another.  
In a prospective study (paper II), in 1577 stroke-free subjects, we tested whether albuminuria and 
carotid atherosclerosis in 1994 predicted cognitive function in 2007.  
In a cross-sectional case-control study (paper III) with 140 cases and 58 controls, we tested 
associations between cardiovascular risk factors, the ApoE ε4 allele and parental LOAD on the one 
hand, and fully automated MR volumetric findings on the other. Besides, whether fully automated 
MR volumetric findings could distinguish 25 cases with subjective memory complaints (SMC) and 115 
cases with MCI from controls.  
In the cross-sectional case-control studies (papers I and III), we gathered thorough information on 
the dispersion of probable LOAD in the participants’ families. Furthermore, we had comprehensive 
data on cognitive function, cardiovascular risk factors, ApoE genotype and fully automated MR 
volumetry of cerebral structures for all participants. Research on AD and CSVD that has incorporated 
all these variables has been sparse, and there has been none in Norway.  
 
Introduction and background 
Dementia is, after cardiovascular disease, the leading cause of death in older adults [42]. The major 
causes of dementia are, in declining order, AD, cerebrovascular disease, dementia of Lewy bodies 
(DLBD) and frontotemporal dementia (FLD) as shown in figure 6 [1]. They are all, with the exception 
of cerebrovascular disease, neurodegenerative diseases [43-45]. Worldwide, about 40 million people 
have dementia, a number that is expanding and expected to double in 20 years [43,46]. 
In Europe, about 6 % of the population over the age of 65 has dementia [47]. In Norway, with its 5.3 
million inhabitants, only crude estimates exist of how many persons have dementia. According to 
“Aldring og Helse” (a Norwegian governmental health agency), probably 70 000-104 000 Norwegians 
have dementia. The personal and societal toll of dementia is obvious. In Norway, around 80 % of 
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nursing home residents and more than 40 % of people over 70 receiving domiciliary care have 
dementia [48]. 
Figure 6. Prevalence of the major dementia types 
 
Figure: The major dementia types in persons over the age of 75                                                                 
(permission granted from professor Nenad Bogdanovic, Karolinska Institutet, Stockholm) 
Our focus in the Tromsø Dementia Study (papers I and III) is primarily on LOAD – sporadic versus 
familial – and CSVD. Studies have shown that there may be connections between vascular and AD 
pathology in the evolution of clinical VCI and AD [49]. We wanted to assess the roles of 
cardiovascular and genetic risk factors in persons from a general population. Other diseases or 
conditions that cause dementia are therefore not discussed. 
 
Cognitive impairment and dementia 
Dementia due to AD and CSVD is the result of long term processes lasting 20-30 years or more [50]. 
When a person gets the impression of having cognitive impairment, without others noticing it and 
achieving normal scores on cognitive testing, the condition can be referred to as subjective memory 
complaints (SMC), subjective cognitive decline or subjective cognitive impairment [51-54]. This does 
not necessarily represent neurodegenerative disease or CSVD, but can have a number of causes, 
particularly depression [55]. When SMC stems from a neurodegenerative disease such as AD, 
representing a prodromal stage of AD, MCI and dementia develops subsequently (figure 7) [9]. MCI is 
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defined as a cognitive decline greater than that expected for age and education, and which does not 
interfere notably with daily activities [56]. Dementia represents a gradual cognitive decline so large 
that it interferes notably with daily activities. Different sets of criteria are employed to diagnose and 
distinguish between AD, vascular dementia and other dementia types. For instance, there are 
NINCDS-ARDRDA criteria, ICD-10 criteria and the DSM criteria for AD, and own DSM criteria and ICD-
10 criteria as well as the NINDS-AIREN criteria for probable vascular dementia [57-60]. The different 
sets of criteria for dementia have in common that there must be cognitive impairment in at least two 
cognitive domains. 
Figure 7. Progression of AD and cognitive impairment 
 
Figure: Jessen et al., Alzheimer’s Dementia, 2014;10(6):844-52                                                              
(permission granted from publisher) 
Risk factors and risk markers 
Cardiovascular risk factors are considered to be risk factors for CSVD, and are suggested to also be 
risk factors for AD [49,61-65]. Homocysteine (Hcy) appears to be a risk factor for both VaD and AD 
[66,67]. However, the roles of cardiovascular risk factors and homocysteine in CSVD and AD have not 
been sufficiently clarified. 
Many genetic risk factors for AD have been discovered. Mutations in the amyloid precursor protein 
(APP) gene and the presinilin genes (PSEN1 and PSEN2) are fully penetrant and bring about familial 
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EOAD, age of onset typically being between 30-60 years. However, less than 1 % of patients with AD 
have these mutations, and most EOAD patients are sporadic [68]. Epidemiological studies of EOAD 
indicate that the vast majority are non-familial, accounting for about 4–6 % of all AD [69]. 
The most common form of AD, LOAD, occurs most often sporadically as sporadic LOAD, but also 
recurs in families as familial LOAD. Familial LOAD can be defined as two or more biological family 
members having LOAD [4,70]. Members of families with an aggregation of LOAD, i.e. familial LOAD, 
have a considerably higher risk of developing LOAD [71]. After advanced age, having a first-degree 
family history of LOAD, especially when a parent is affected, is the most significant risk factor for 
developing LOAD [72]. The genetically mediated risk in familial LOAD is only partially explained by the 
ApoE ε4 allele, which is found in less than 40 % of persons with familial LOAD [70]. Familial and 
sporadic LOAD might therefore differ in causal factors and pathophysiology [72,73]. 
The ApoE ε4 allele is the major known genetic risk factor for LOAD. In a recent study by Cruchaga et 
al., polygenic risk score of sporadic LOAD revealed a shared architecture with familial LOAD, sporadic 
EOAD (age of onset <65 years without documented familial history of AD) and familial EOAD [6]. 
Sporadic and familial LOAD still largely constitute a genetic conundrum [43,74-80]. The ε 4 allele 
brings about a dose-dependent increase in the risk of developing LOAD [18]. In ApoE ε4 homozygotes 
the lifetime risk for LOAD is more than 50 %.                                                                                                                 
ApoE is essential for normal lipid homeostasis in the brain, and ApoE isoform might influence several 
physiologic pathways [18]. ApoE is produced in many tissues, such as in the brain, skin, liver, spleen 
and kidneys, and maintains the structural integrity of lipoproteins and facilitates their solubilization 
in the blood [81,82]. The ε4 allele may cause a gain of toxic function in the ApoE protein, or loss of 
neuroprotective function, or both [18]. The consensus is that differential effects of ApoE isoforms on 
Aβ aggregation and clearance, play a major role in LOAD pathogenesis. 
Most of the known genetic risk factors constitute only a minimal or low risk for LOAD (figure 8) [43]. 
Genome-wide association studies, together with exome and genome sequencing, have pointed out 
three particularly important biological processes in AD pathogenesis [8]. These are cholesterol 
metabolism, endosomal recycling and inflammation and the brain’s immune system (figure 8) [43].                 
A polygenic hazard score based on known single-nucleotide polymorphisms in genes linked to AD, 






Figure 8. Genes linked to AD 
 
Figure: Scheltens et al., The Lancet, Vol. 388, July 30, 2016 (permission granted from publisher)  
Albuminuria is a surrogate marker of endothelial dysfunction and microvascular disease anywhere in 
the circulation [84]. It is a risk marker of renal endothelial dysfunction, chronic kidney disease and 
cardiovascular disease [85]. Albuminuria and endothelial dysfunction are considered to be precursors 
of atherosclerosis [86]. Albuminuria might also be a risk marker of cerebral endothelial dysfunction 
and vascular cognitive impairment (VCI) [84,87]. The brain and the kidneys are both highly 
vascularized end organs and share hemodynamic characteristics. Albuminuria might therefore 
express cerebral endothelial dysfunction [87,88].  
Ultrasonography of the internal carotid arteries gives measurements of intima-media thickness (IMT) 
and total plaque area (TPA). Several prospective studies have shown that subclinical carotid 
atherosclerosis is inversely associated with cognitive function [89]. Increased IMT and TPA, besides 
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being risk factors for intracerebral vascular disease, are potential risk markers of cognitive decline 
[89]. 
Biomarkers 
Biomarkers can detect AD at different stages of the disease course, as shown in figure 9 [8]. They can 
also assess the amount of cerebrovascular disease [23,90]. 
Cerebral imaging and analysis of CSF are performed to assess biomarkers of AD in the clinical routine 
[43]. The core CSF biomarkers are Aβ42, phosphorylated tau (p-tau) and total tau (t-tau). Due to 
inadequate sensitivity and specificity, the core CSF biomarkers are not suitable for wide clinical 
implementation [91]. They are unable to distinguish satisfactorily between the dementia subtypes or 
predict transition between the different stages of cognitive impairment. Hence, lumbar puncture and 
measurement of cerebrospinal fluid Aβ42, t-tau and p-tau are carried out to varying extents 
clinically. However, quantification of the core CSF biomarkers is routinely used in memory clinics and 
to enrich study and trial samples [91,92]. 
Computed tomography (CT) imaging and magnetic resonance imaging (MRI) of the brain are the 
main imaging modalities in the clinical routine for cognitive impairment. They can detect other 
intracranial causes of cognitive impairment, for example idiopathic normal pressure hydrocephalus, 
tumors and stroke, and assess the amount of cerebrovascular disease [23,43,93]. Several visual 
rating scales that estimate for instance atrophy of cerebral structures, are applied to diagnose 
dementia and distinguish between dementia subtypes [94]. In AD and frontotemporal dementia, 
cerebral structures atrophy in a characteristic temporal pattern [93,95]. 
MRI has better resolution than CT imaging, and is utilized in the early diagnosis of AD and 
frontotemporal dementia [93,96-98]. In AD, MR volumetry can show distinct changes in 
hippocampus, amygdala, lateral ventricles and medial temporal lobes [96-98]. Atrophy of association 
cortices in the temporal, frontal and parietal lobes occurs later in the course of AD [99].                                                                          
Features of CSVD shown on MRI include WMH, small subcortical infarcts, microbleeds, lacunes, 
perivascular spaces and brain atrophy [90].                                                                                                                 
Promising MRI research techniques to visualize CSVD and its lesions include ultra high field strength 
MRI (>3.0 Tesla), diffusion tensor imaging of detailed structural connectivity and magnetisation 
transfer assessment of white matter myelination [90]. 
The prevailing view is that AD has its origin in the transentorhinal and entorhinal cortex of the medial 
temporal lobes, and subsequently spreads to other locations. However, it is possible that 
neurodegeneration starts simultaneously in other locations, including the nucleus basalis of Meynert 
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located deep in the frontal lobes and the locus coeruleus located in the pons of the brainstem [95]. 
The nucleus basalis of Meynert provides the single major source of cholinergic innervation to the 
entire cerebral cortex [100]. The locus coeruleus’ is the major noradrenergic nucleus of the brain. Its 
efferent fibers are highly branched and reach virtually all parts of the central nervous system [34]. 
The nucleus basalis of Meynert and the locus coeruleus have in common that they send fibers 
directly to the cerebral cortex, without synaptic interruption in the thalamus [34]. 
Manual MRI-volumetry of cerebral structures is not cost-effective as it is too time-consuming. Fully 
automated brain volumetry has therefore been developed to help diagnose AD and frontotemporal 
dementia in the clinical routine [93,101-103]. The fully automated volumetric software NeuroQuant 
can back up other clinical investigations in diagnosing AD [104-106]. 
Positron emission tomography (PET) imaging is important in AD research, for example to enrich study 
and trial samples. It is, however, not yet cost-effective in the clinical diagnostic work-up of cognitive 
impairment [91,107-109]. PET amyloid imaging using the tracer Pittsburgh Compound-B (PiB) 
suggests that 20-30 % of cognitively normal persons have positive PiB scans, while about 60 % of 
persons with MCI have positive PiB scans [110]. Fluorodeoxyglucose (FDG) PET can measure glucose 
hypometabolism in the brain. Synaptic activity in the brain is associated with glucose metabolism, 
persons with AD showing a characteristic pattern of hypometabolism in the temporoparietal regions 
bilaterally [4].  
The ApoE ε4 allele is the major known genetic risk factor for LOAD, and a biomarker for AD [111]. 
However, it has little clinical applicability, as it only to a limited extent predicts cognitive decline or 












Figure 9. Temporal model of AD biomarkers 
 
Figure: Dennis Selkoe and John Hardy, EMBO Molecular Medicine, Vol. 8, No. 6, 2016                        





Aims of the thesis 
This thesis consists of three papers. A primary aim was to test associations between cognitive 
function on the one side, and cardiovascular and genetic risk factors on the other, in a general 
population. 
The specific aims were: 
- to test whether tHcy, cardiovascular risk factors and fully automated MR volumetric measurements 
of cerebral structures in persons with MCI differ between persons from families with or without 
probable familial LOAD. Paper I 
 
- to test whether albuminuria and carotid atherosclerosis independently predict cognitive function 13 
years later. Paper II 
 
- to test whether fully automated MR volumetric findings were associated with probable parental 
LOAD, ApoE ε4 genotype, tHcy and cardiovascular risk factors and to also test whether fully 
automated MR volumetry of cerebral structures could distinguish persons with SMC and MCI from 
cognitively healthy controls. Paper III 
 
Materials and methods 
All subjects and data in this thesis are from the Tromsø Study. The Tromsø Study started in 1974 with 
its first survey, Tromsø 1, primarily to address cardiovascular diseases that at that time constituted 
an overwhelming health problem. Every 6-7 years the Tromsø Study has a new survey, and the last, 
Tromsø 7, was in 2015-2016.                                                                                                                                                           
Since Tromsø 4 (1994-95), the survey has had two visits, with a more comprehensive examination in 
the second visit. Eligible candidates for the second visit are decided already before the first visit.  
Gradually, other conditions and chronic diseases gained attention, such as cognitive impairment and 
AD. Cognitive testing was introduced in Tromsø 5 (2001-2002), and has since been a part of the 
second visit in the Tromsø Study. The Tromsø Study cohort has been described earlier [113].  
All Tromsø Study participants are from the municipality of Tromsø. The number of inhabitants 
increased gradually from appr. 42 000 inhabitants in 1974 to 65 000 inhabitants in 2008. In Tromsø I, 
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8866 men were invited to the survey, whereof 6959 attended. In Tromsø 6 (2007-08), 19762 persons 
were invited, wherof 12984 attended.  
The University hospital of North Norway, which is located in Tromsø, is the only hospital in the 
region. The next-nearest hospital is 250 km away. Relevant data on Tromsø Study participants can be 
easily accessed and the cohort of the Tromsø Study is therefore well characterized. 
The Tromsø Dementia Study (papers I and III) is a cross-sectional nested case-control study in Tromsø 
6. Paper II presents a prospective study based on data on subjects who participated in the second 
Tromsø 4 and Tromsø 6 visit. 
Ethics 
Persons who answered "Yes" to the question “Has your memory declined” in the Tromsø 6 first visit 
questionnaire were potential cases for the Tromsø Dementia Study. Neurodegenerative diseases lack 
effective treatment. It would therefore be unethical to diagnose cognitive impairment and potential 
neurodegenerative disease in those who do not suspect they are suffering from these conditions. 
The Tromsø Dementia Study (papers I and III) and the prospective study (paper II) were approved by 
the board of the Tromsø Study and the Regional Ethical Committee of Northern Norway. The Tromsø 
Dementia Study was also approved by the Norwegian Social Science Data Services. 
Study population paper I  
A total of 19 762 persons were invited to the first Tromsø 6 visit, 12 984 taking part. Those who 
fulfilled the following criteria were invited to take part in more comprehensive testing in the second 
visit: first visit participants aged 50-62 and 75-84 years, a 20 % random sample of men and women 
aged 63-74 years and subjects who had attended the second examination in Tromsø 4 and were aged 
<75 years in 1994. Out of 11484 eligible participants, 7307 attended the second visit. 
The following is a brief description of the population, including some supplemental information. The 
second Tromsø 5 visit included three cognitive tests: the finger-tapping test (FTT), the digit-symbol 
coding test (DST) and the twelve word test which is comprised of two parts [114-116]. The 2.5 
percentile of these cognitive test scores were defined as cutoff values for low cognitive test scores 
for the second Tromsø 6 visit. Low test scores were therefore <4 for the word test part 1, <5 for the 
word test part 2, <23.0 for the FTT and <12 for the DST. The Mini Mental State Examination (MMSE) 
was introduced in Tromsø 6 and has by definition a low test score of <24 [117].  
Persons who answered "Yes" to the question “Has your memory declined” on the Tromsø 6 first visit 
questionnaire and had one or more low cognitive test scores in the second Tromsø 6 visit were 
eligible as cases for the Tromsø Dementia Study. Persons who answered "No" to the question “Has 
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your memory declined?” and who had cognitive test scores above the cutoff values in the second 
Tromsø 6 visit were eligible as controls.  
Eligible cases were invited by mail to take part in the Tromsø Dementia Study. They were informed of 
having achieved low cognitive testing scores and that they were therefore of interest as participants 
in cognitive impairment research. The letter informed them that in addition to comprehensive 
cognitive testing, a cerebral MRI would be performed and a blood sample would be drawn during the 
visit. Totally, 403 eligible cases were invited, whereof 139 assented. Eligible controls matched for sex 
and age were at the same time invited by mail. They were informed of having achieved normal 
cognitive testing scores and were therefore of interest as controls in cognitive impairment research. 
They were also informed about cognitive testing, cerebral MRI and the drawing of a blood sample. A 
total of 180 were invited, 73 taking part.  
Cases and controls with stroke (not lacunar) on cerebral MRI were excluded. The number of cases 
and controls diminished to 103 and 58 respectively due MRI results and cognitive testing in the 
Tromsø Dementia Study. This is shown in figure 1 of the paper. The remaining cases were considered 
to have probable prodromal sporadic LOAD, familial LOAD or to be intermediary and to also possibly 
have coexisting CSVD.  
The participants were classified into four groups. The controls were in group 1. Group 2 consisted of 
cases without knowledge of any biological relatives with LOAD. These were considered to have 
probable prodromal sporadic LOAD. Group 3 consisted of cases who had one biological relative with 
LOAD with onset of LOAD after the age of 65. Group 4 consisted of cases with ≥2 biological relatives 
on one side of their family with the onset of LOAD after the age of 65. The cases in group 4 were 
considered to have probable prodromal familial LOAD. 
Group 4 in an alternative classification of groups 3 and 4 consisted of cases with a parent or parents 
with LOAD. These cases were considered to have probable prodromal familial LOAD based on less, 
but more reliable information. Group 3 then consisted of cases with other biological relatives with 
LOAD.  
Study population paper II 
All persons aged ≥25 years were invited to the first Tromsø 4 visit, 27 159 persons taking part. All 
participants between age 55 and 74 and 5-10 % representative samples of the other birth cohorts 
aged 24-84 years (9 057 in total) were invited to the second visit, 7 965 taking part. In Tromsø 4, 
analysis of albuminuria and ultrasound examination of the right internal carotid artery were 
introduced as part of the second Tromsø Study visit.  
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Eligible persons were those who had taken part in both Tromsø 4 and Tromsø 6, had albuminuria and 
ultrasound examination of the right internal carotid artery results, blood tests results and Tromsø 4 
and Tromsø 6 questionnaire information on vascular risk factors. Moreover, they had to have 
cognitive test results from Tromsø 6 DST and FTT. Exclusion criteria were self-reported stroke or 
missing information on self-reported stroke in Tromsø 6, and macroalbuminuria in Tromsø 4 or 
Tromsø 6. Figure 1 in paper II provides a detailed description of the selection of participants.  
Study population paper III 
The sample consists of 12 additional cases with MCI and 25 cases with subjective memory complaints 
(SMC), all being in addition to the cases and controls of paper I. 
Of the 12 extra cases with MCI, 6 cases were not included in paper I because of incomplete 
information on probable LOAD in second and third-degree relatives and 6 cases were not included 
because they had reported an earlier stroke which there were no signs of on MRI. These 12 cases 
were now included because information on LOAD in second and third-degree relatives was not 
necessary and because they probably had not had a stroke, MRI showing no signs of this. 
MMSE was introduced for the first time in Tromsø 6. The study personnel who administered the 
cognitive tests were new to this examination. This may account for testing of delayed recall in MMSE 
being unintentionally not carried out upon many of the second Tromsø 6 visit participants, which 
resulted in apparently low MMSE scores. Unfortunately, this passed unnoticed until the survey had 
ended. Participants with MMSE score <24 and with missing delayed recall testing, who answered 
"Yes" to “Has your memory declined” in the Tromsø 6 questionnaire and had normal scores on the 
finger tapping test, digit symbol coding test and twelve word test therefore appeared to be eligible 
cases. Several of these were therefore invited to and took part in the Tromsø Dementia Study. They 
could not, however, be confidently defined as cases. Some of them also had other missing variables 
in the MMSE, such as abstract thinking and subtractions. 
In the event of missing results from cognitive testing in the second visit of Tromsø 6 – among other 
considerations – repeated cognitive testing had been implemented in the Tromsø Dementia Study. 
All these participants with missing MMSE scores in the MMSE in Tromsø 6, had MMSE scores >24 in 
the Tromsø Dementia Study. They achieved, on average, higher scores than the true cases with MCI 
in Tromsø 6. We therefore chose to define these 16 participants as having subjective memory 
complaints (SMC). The mean MMSE score was 28.9 for the 58 controls, 27.8 for the 16 SMC cases 
and 26.9 for the 115 MCI cases in the Tromsø Dementia Study.  
The remaining 9 cases in the SMC group had, in error, been invited as cases to the Tromsø Dementia 
Study because of their DST scores. They answered “Yes” to “Has your memory declined” in the 
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Tromsø 6 questionnaire, but had DST scores that ranged from 12 to 16 (mean score 13.7) which was 
between the 2.5 and the 7.5 percentiles of the DST score for Tromsø 5. We therefore chose to define 
these 9 participants as also having SMC. 
Papers I and III – The Tromsø Dementia Study 
Cases and controls attended the Tromsø Dementia Study in the period April 2008-June 2009, which 
was within a few months after the second Tromsø 6 visit. A geriatrician and a research nurse 
administered the study. They invited cases and controls, carried out interviews, cognitive testing, 
physical examinations, drawing of blood samples and scheduled cerebral MRI appointments. The 
number of participants received each day was 3-4, which was the number of MRI slots the 
radiological department at the University Hospital of North Norway had available for the study. All 
but a few participants were accompanied by a family member or friend who could validate the 
participant’s information and answer questionnaires on collateral information. In unaccompanied 
participants, questionnaires concerning collateral information were answered later by relatives and 
returned by mail. Data on blood pressure, body mass index (BMI) and smoking, were obtained from 
Tromsø 6 [113]. 
Interviews 
All participants underwent structured interviews, nearly all being witnessed by a companion. They 
were interviewed in detail about their education, sensory impairment, gait and motility, medication, 
alcohol and drugs usage, social and physical activities, earlier diseases and specifically about diseases 
or conditions that could cause or resemble cognitive impairment. 
The Montgomery and Aasberg dementia rating scale (MADRS) was applied to assess depression in all 
participants [118]. 
Petersen’s original construct for MCI was applied [56]. We did not use later constructs with amnestic 
and nonamnestic subtypes of MCI [119]. The NINCDS-ADRDA criteria for AD were applied [120]. 
Cases and controls were interviewed in detail about whether they had biological relatives with 
probable LOAD. They were asked how many brothers and sisters they, their parents and maternal as 
well as paternal grandparents had. They were then asked how many of their relatives had or had had 
probable AD after the age of 65. They were specifically asked whether relatives with dementia might 
have or have had other conditions or diseases that cause dementia, such as a stroke or Parkinson’s 
disease. Cases with MCI (paper I) were classified into three groups based on this mapping of the 
dispersion of probable LOAD. Those who had no relatives with probable LOAD were considered to 
have probable prodromal sporadic LOAD (group 2). Those with 2 or more biological relatives with 
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probable LOAD were considered to have probable prodromal familial LOAD (group 4) and those with 
1 biological relative with probable LOAD (group 3) were considered to be intermediate. 
In an alternative classification of cases with biological relatives with probable LOAD (cases in groups 3 
and 4), cases with one or two parents with probable LOAD formed group 4, and were considered to 
have probable prodromal familial LOAD. Cases with other biological relatives with probable LOAD 
formed group 3, and were considered to be intermediate. 
In paper III, cases and controls were classified as either having had one or two parents with probable 
LOAD (probable parental LOAD) or as not having had parents with probable LOAD.  
Cognitive tests  
A wide range of cognitive tests are used to examine cognitive function [114]. There is, in dementia, a 
deterioration of higher cortical functions such as memory, learning, understanding, judgment, 
thought, language and orientation in time and place [121]. Numerous cognitive tests have been 
developed to detect deterioration of skills in these cognitive domains. The tests applied in the 
Tromsø Study and the Tromsø Dementia Study are ones widely used to diagnose MCI and dementia. 
The four cognitive tests used in the Tromsø Study (FTT, DST, MMSE and the 12-word test) were also 
applied in the Tromsø Dementia Study. The clock drawing test and the trail making tests were 
additional cognitive tests in the Tromsø Dementia Study.  
FTT mainly tests psychomotor tempo [114,116,122].  Participants tapped as quickly as they could 
with their index finger on a key on the keyboard of a computer for 10 seconds. This was carried out 
four consecutive times with the right and left index finger. The first time was for practice and to 
become familiar with the exercise. The mean number of taps of the non-dominant index finger for 
the last three performances were used in the analyses. 
DST tests psychomotor performance. Motor persistence, sustained attention, response speed, 
visuomotor coordination and incidential memory influences performance [114]. At the top of a sheet 
of paper were two adjoined rows of boxes, 9 boxes in each row. The boxes of the top row contain 
symbols, each being allocated to a number (from 1 to 9) in the bottom row boxes. Below this 
number-symbol key are several equivalent adjoined rows of boxes filled in with numbers but not 
symbols. In the practice round, participants wrote in the first seven blank symbol boxes the missing 
symbols associated with the numbers in the row below. After this they had 90 seconds to fill in as 
many symbols as possible in the blank symbol boxes [116]. The achieved number of symbols was 
used in the analyses. 
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MMSE is the world’s most widely used cognitive screening tool. It is a global cognitive test that 
crudely tests different cognitive domains such as orientation to time and place, learning, recall, 
calculation, language and visual construction [114,117,121]. Test performance is influenced by age, 
education, language problems and test situation. 
The 12-word test is a modification of the California Verbal Learning test [115]. Part one tests 
immediate recall, part two tests recognition. Participants were asked to remember a series of words 
presented to them. In part one, 12 nouns were presented to the participant consecutively from a 
booklet, one being displayed every 5 seconds. The examiner simultaneously read the word aloud. 
The participants had two minutes right after this to recall the words [116]. The score range for part 
one was therefore 0 to 12. In part two, 24 nouns were shown from a booklet in the same way as in 
part one. These nouns included the 12 nouns of part 1 intermixed with 12 other nouns. Participants 
replied for each word whether it had been presented or not in the first part. Each wrong answer was 
scored -1 and each correct answer was scored 1. The score range for part two was therefore -24 to 
24. 
The clock drawing test tests visuospatial ability. Performance is influence by participants’ attention, 
understanding of numbers and executive function [121,123]. There are many versions of the clock 
drawing test. We used a 7 item version, 7 being the best score and 0 the poorest. 
The trail making test tests attention, cognitive flexibility, visuomotor tracking and executive function 
[114,121,124]. It is comprised of trail making A and trail making B. In trail making A, a line is drawn as 
quickly as possible between consecutively numbered circles, numbered 1 to 25. The numbered 
circles are randomly placed on a worksheet. In trail making B, numbered circles 1-13 and lettered 
circles A-L are randomly placed on a worksheet. A line is to be drawn as quickly as possible that 
alternates between consecutive numbers and letters. The line therefore starts with 1 and A and ends 
with 13 and L. The time needed to complete the tasks was used in the analyses. 
Collateral information 
Cases and controls who consented to participate in the Tromsø Dementia Study, received three 
questionnaires by mail on collateral information. The vast majority of questionnaires were answered 
by spouses or by other family members or friends. 
The informant questionnaire on cognitive decline in the elderly (IQCODE) is the most commonly used 
informant dementia assessment [125,126]. The IQCODE’s 16 questions compare present cognitive 
function to cognitive function 10 years earlier. Each answer is scored from 1 to 5. A score of 1 is best, 
and indicates a much better cognitive function now than 10 years earlier. A score of 3 indicates 
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unaltered cognitive function, and a score of 5 much worse cognitive function. A mean score of 
around 3.5 indicates cognitive impairment.  
The rapid disability rating scale-2 (RDRS-2) assesses activities of daily living [127]. We used the 
Norwegian version, which uses the same 18 considerations but splits them into 21 items. They are 
scored 1-4, and outcome scores therefore range from 21 to 84, 21 representing the best functional 
level. 
The behavior and mood disturbance (BMD) scale assesses behavioral and psychological symptoms in 
dementia [128]. It contains 20 questions on behavior and 13 questions on cognition. All answers are 
scored from 0 to 4, scores of ≤40 for behavior and ≥26 for cognition being considered to be normal. 
Blood samples 
Blood samples were drawn from all participants to test sedimentation rate, sodium, potassium, ApoE 
genotype, total plasma homocysteine (tHcy), cobalamin, folic acid, phosphate, ionized calcium, free 
thyroxine and thyroid stimulating hormone. Other blood test results were taken from the Tromsø 
Study. All blood samples were analyzed at the Department of Clinical Chemistry, University Hospital 
of North Norway. 
Magnetic resonance imaging 
Cerebral MRI was carried out on all participants, and served two purposes. The first was to reveal 
intracranial pathology, the second to carry out fully automatic volumetric measurements of cerebral 
structures using the software package NeuroQuant. In the statistical analyses, the volumetric 
measurements were surrogate markers for preclinical and prodromal AD. 
Neuroquant has been validated against manually traced volumes and semiautomatic methods 
[129,130]. The volumes of cerebral structures were intracranial volume corrected to adjust for 
differences in brain size, by summing the bilateral volumes of each cerebral structure and expressing 
it as a percentage of the intracranial volume. Papers I and III provide more detailed information.  
Paper II 
All data in paper II is taken from Tromsø 4 and Tromsø 6 [113]. Main predictor variables were urinary 
albumin-creatinine ratio (ACR) and ultrasonographic measurements of right internal carotid artery 
intima media thickness (IMT) and total plaque area (TPA). ACR correlates well with the quantification 
of albuminuria in 24-hour urine collection [131]. The methodology for these measurements have 
been described previously [132,133]. Collection of urine samples for albumin and creatinine 
measurements and ultrasonography of the right internal carotid artery for measurement of IMT and 
TPA were performed in the second Tromsø 4 and Tromsø 6 visits. 
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The outcome variable was cognitive function in the second Tromsø 6 visit, primarily assessed by DST 
and FTT.  
Trained nurses recorded height, weight and blood pressure. Information on education, 
antihypertensive treatment, alcohol consumption, smoking, diabetes mellitus and coronary disease 
was taken from Tromsø 4 questionnaires [113].  
Statistical analyses 
Characteristics were displayed as means (standard deviation), medians (interquartile range), 
numbers or percent. The independent t-test, the Mann-Whitney test and the chi-square test were 
used to calculate differences between groups. Linear regression was applied to test associations and 
analysis of covariance (ANCOVA) was used to compare groups. 
Apo E genotype in papers I-II was coded as a binary variable, heterozygote or homozygote for the ε4 
allele on the one hand or not having the ε4 allele on the other. 
The statistical analyses in paper I and III were performed using SPSS version 18, and in paper II using 
SPSS version 22. 
Paper I 
Comparisons between the case groups (groups 2-4) and the control group (group 1) were performed 
using ANCOVA. 
There was an interaction between gender and groups 1-4 for tHcy level. Analyses were therefore 
performed gender specific. Outcome variables were tHcy, volumes of cerebral structures and 
cardiovascular risk factors. Using tHcy as outcome variable, we adjusted for age, systolic blood 
pressure, serum cobalamin, serum folate, BMI, estimated glomerular filtration rate (eGFR) and 
diabetes mellitus [134]. Volumes of cerebral structures and cardiovascular risk factors were adjusted 
for age.  
Paper II 
The subjects were grouped into sex specific ACR quartiles based on Tromsø 4 ACR measurements. In 
ANCOVA, ACR, ∆ACR (ACR Tromsø 6 minus ACR Tromsø 4), IMT and ∆IMT (IMT Tromsø 6 minus IMT 
Tromsø 4) were ranked sex specifically because ACR, IMT and DST and FTT performance differ 
between genders [114,135,136]. ACR and ∆ACR were ranked into quartiles, and IMT and ∆IMT 
dichotomized into those below versus those at or above the sex-specific median. Adjusted for age, 
sex, education, blood pressure medication, alcohol intake and cardiovascular risk factors, ACR and 
∆ACR quartiles 2-4 were compared with ACR and ∆ACR quartile 1 respectively. We also tested 
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whether there were significant differences on the cognitive test scores between those with the 
smallest and largest IMT, and between those with the smallest and largest ∆IMT. 
Multivariate linear regression was applied to test whether ACR (Tromsø 4), ∆ACR, IMT (Tromsø 4) 
and ∆IMT predicted Tromsø 6 cognitive test scores. The analyses were adjusted for the same 
variables as in ANCOVA.  
The correlation between IMT and TPA was high (Spearman’s r = 0.50), and in multiple regression 
both had approximately equivalent F-changes. IMT was preferred in the analyses as it, in contrast to 
TPA, brought about an equal number of subjects in the subgroup analysis.  
Paper III 
In ANCOVA, we tested whether sex and age adjusted mean volumes of cerebral structures differed 
significantly between cases with SMC or MCI and controls. 
Receiver operating characteristic analysis was used to test the diagnostic ability of fully automated 
volumetric measurements to distinguish cases with SMC and MCI from controls. 
In linear regression, associations between volumes of cerebral structures on the one side, and tHcy, 
genetic risk factors and cardiovascular risk factors on the other were tested. There was a borderline 
significant interaction (p = 0.070) between sex and probable parental LOAD for hippocampal volume. 
In paper I, this interaction was significant (p = 0.027). Therefore additional analyses were performed 
with hippocampal volume as outcome, stratified by gender and probable parental LOAD. 
 
Main results 
Paper I – Women with MCI and probable prodromal familial LOAD differ from women with 
MCI and probable prodromal sporadic LOAD 
Women with MCI and probable prodromal familial LOAD did not have significantly higher tHcy than 
controls, unlike the other case groups. Moreover, in contrast to women with MCI and probable 
prodromal sporadic LOAD, they had significantly smaller volumes of amygdala and hippocampus, and 
significantly larger volumes of the lateral ventricles than controls.  
In the alternative classification of cases with probable prodromal familial LOAD, using the Bonferroni 
correction, women with MCI and probable prodromal familial LOAD had significantly smaller 
hippocampal volume than controls, women with MCI and probable prodromal sporadic LOAD and 
women with MCI in the intermediate group (p = 0.001, 0.040 and 0.003, respectively). 
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Correspondingly, they had significantly larger lateral ventricular volumes than women with MCI and 
probable prodromal sporadic LOAD.                                                                                                                                                                          
We found no significant differences between the groups using BMI, systolic blood pressure, total 
cholesterol, eGFR and HbA1c as outcome variables in ANCOVA.  
In the sample, 37.3 % of the participants were carriers of the ApoE ε4 allele (1.9 % ε2/ε4 
heterozygotes, 5.0 % ε4/ε4 homozygotes and 30.4 % ε3/ε4 heterozygotes). In groups 1-4 in women, 
46 %, 27 %, 39 % and 47 % respectively were carriers of the ApoE ε4 allele. Correspondingly, in 
groups 1-4 in men, 39 %, 41 %, 17 % and 33 % respectively were carriers of the ApoE ε4 allele. In 
groups 1-4 in women, in the alternative classification, 46 %, 27 %, 50 % and 38 % respectively were 
carriers of the ApoE ε4 allele. 
Women with MCI were more likely than men with MCI to have biological relatives with probable 
LOAD. In both genders, more than 65 % of the biological relatives with probable LOAD in groups 1, 3 
and 4 were women. 
Paper II – Albuminuria, carotid atherosclerosis and smoking are early and independent 
predictors of executive function and psychomotor tempo 
Across the ACR-quartiles, for increasing ACR, there was a significant trend of increasing age, BMI, 
systolic blood pressure, current use of antihypertensive medication, current smoking, eGFR, IMT, 
∆IMT, TPA and ∆TPA. 
In multiple regression, higher ACR, higher ∆ACR and larger IMT were independently associated (p = 
0.016, 0.002 and 0.010, respectively) with lower DST score. Higher ∆ACR was associated (p = 0.006) 
with a lower FTT score. Higher ∆IMT had a borderline significant association (p = 0.08) with lower FTT 
score. Smoking was independently associated (p < 0.001) with lower DST and FTT scores. Higher BMI 
was independently associated (p = 0.011) with lower FTT score. Higher eGFR was independently 
associated (p = 0.004) with lower DST score. 
In ANCOVA, there was a significant linear trend (p = 0.003) of a lower DST score for increasing ACR in 
women. In both genders, those with IMT at or above the median scored lower on DST than those 
with IMT below the median (p = 0.031 for women, p = 0.017 for men). Women with IMT at or above 
the median had a significant linear trend (p = 0.006) of a lower DST score for increasing ACR. 
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Paper III – Probable parental LOAD, the ApoE ε4 allele, higher tHcy and higher eGFR are 
independently associated with smaller hippocampal volume, especially in women 
In multiple regression, probable parental LOAD, presence of the ApoE ε4 allele, higher tHcy and 
higher eGFR were independently associated (p = 0.058, 0.015, 0.004 and 0.045, respectively) with 
smaller hippocampal volume. 
Stratified by gender and using the most relevant variables – age, presence of the ApoE ε4 allele, 
probable parental LOAD, tHcy, cobalamin, eGFR and folic acid – the associations strengthened in 
women and diminished in men.  
In age and sex adjusted ANCOVA, hippocampal volume was significantly smaller and lateral 
ventricular volume significantly larger in cases with SMC and MCI compared to controls. In cases with 
MCI, the volumes of amygdala, cerebral cortex and cerebrum were significantly smaller than in 
controls. Cases with MCI had higher volume of white matter hyperintensities (WMH) than controls. 
MR volumetry of the hippocampus and the lateral ventricles distinguished subjects with SMC and 
MCI from controls.  
In receiver operating curve analysis, MR volumetry did not distinguish well between controls and 
SMC, nor between controls and MCI. The area under the curve in SMC and MCI compared to controls 
was less than 0.68 for all volumes of cerebral structures. 
In multiple regression analysis, higher tHcy was significantly associated with smaller volumes of 
hippocampus, amygdala, cerebral cortex and cerebrum and with larger lateral ventricles.  
Higher total cholesterol was significantly associated with larger hippocampal, amygdalar and cerebral 
volumes, and with smaller lateral ventricular volume. 
In the sample, 38.5 % of the participants were carriers of the ApoE ε4 allele (2.0 % ε2/ε4 
heterozygotes, 4.0 % ε4/ε4 homozygotes and 32.3 % ε3/ε4 heterozygotes). Of controls, participants 




The Tromsø Dementia Study (papers I and III) is a cross-sectional nested case control study in Tromsø 
6. Advantages of cross-sectional case control studies are that many exposures can be examined, and 
that associations between them and disease outcomes can be assessed. They are therefore 
hypothesis generating. However, they can not test causality. 
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Paper I had 161 participants, comprising 58 controls and 103 cases with MCI. Paper III had 198 
participants, comprising 58 controls, 25 cases with SMC and 115 cases with MCI.                                               
The small sample sizes entail that the chances of making statistical type 1 and type 2 errors are 
relatively high. A type 1 error is to reject a null hypothesis when it is true, and a type 2 error is failing 
to reject a null hypothesis when it is false [137]. 
Paper II is a prospective cohort study based on data from Tromsø 4 and Tromsø 6. Participants (1577 
in total) were selected from the Tromsø Study cohort, and had participated in the second visits in 
both Tromsø 4 and Tromsø 6 [113]. Cohort studies seek associations between exposures and disease 
outcomes. They are, like cross-sectional case-control studies, hypothesis generating and can not test 
causality. Causal associations can, however, be expected if Bradford Hill criteria are sufficiently 
fulfilled. Due to the high number of participants, the chances were small of making type 1 and 2 
errors. 
Internal and external validity 
Internal validity expresses whether the study results are valid for the population from which the 
study sample is drawn. External validity expresses whether the study results are also valid for other 
populations, such as the general population [137]. Internal validity is threatened by error and bias. 
Error and bias 
 “Man approaches the unattainable truth through a succession of errors” (Aldous Huxley, 1894-
1963). Errors, whether they be random or systematic, are common in science. Error and bias can 
occur in all stages of a research project [137]. Bias can be defined as a systematic error in the design 
or conduct of a study [138]. Bias is an error which affects one group more than another, and is 
therefore more important than random errors which affect comparison groups equally. Bias can 
distort associations and create non-existent associations. The amount of bias and error in a research 
project determines the internal validity of the results – to what extent they are valid for the 
population the study sample is drawn from. If the sample is representative of the population it is 
drawn from, and the study results are not erroneous or biased, then the results have internal 
validity. If this population is representative of the general population, then the results have external 
validity for the general population.  
A common broad classification of error and bias divides this into selection bias, information bias and 
confounding. There are numerous kinds of bias, such as interpretation bias, where the investigator 





Bias can result from the choice of study population. Volunteers tend to differ in many characteristics 
compared to non-volunteers, e.g. income and health status. Selection bias occurs when a systematic 
error in the ascertainment of study subjects results in a tendency that distorts the measure 
expressing the association between exposure and outcome [138].  
In the Tromsø Dementia Study, persons with low cognitive test scores in the second Tromsø 6 visit, 
who also had answered “Yes” to the question “Has your memory declined” on the first Tromsø 6 visit 
questionnaire, were invited as cases. The questionnaire inclusion criterion was due to ethical 
concerns. A considerable proportion of persons with AD are unaware of their cognitive impairment 
[139]. It would therefore be unethical to diagnose a neurodegenerative disease for which there is no 
effective treatment, without permission. Persons without subjective memory complaints who 
answered “No” to the question “Has your memory declined” on the questionnaire, and with low 
cognitive test scores in the second Tromsø 6 visit, were therefore not invited to the Tromsø 
Dementia Study. They might differ in several aspects from the cases who attended. 
The number of invited cases to the Tromsø Dementa Study was 403, 139 taking part. Cognitive 
impairment in invited cases might have contributed to the low participation. The invited cases who 
did not take part might differ from attendees in several aspects. 
The number of invited controls was 180, 73 taking part. Of these, 15 were excluded from the study 
(figure 1, paper I). The invited controls who did not take part might differ from the attendees in 
several characteristics [137]. The low attendance rate in the Tromsø Dementia Study increases the 
likelihood of selection bias. For example, among the 58 controls in the Tromsø Dementia Study, 41 % 
were carriers of the ApoE ε4 allele. This is clearly more than expected in healthy controls. One 
explanation might be that persons with AD in their families were more willing to take part. 
Four different cognitive tests were used to select cases with MCI. It was sufficient to score below the 
cutoff value on one test to be defined as a case. Table 1 in paper I shows how the cases in groups 2-4 
in men and women differ with regard to which cognitive tests defined them as cases. The results of 
between-group comparisons might therefore be biased. It might have been better to select all cases 
with MCI in the same way. 
In paper II, all participants were without self-reported stroke and macroalbuminuria and had 
measurements of ACR, IMT and TPA from both Tromsø 4 and Tromsø 6 and cognitive test scores 
from Tromsø 6. The Tromsø Study has had a high attendance rate, 82 % in Tromsø 2, 79 % in Tromsø 
3, 75 % in Tromsø 4, 81 % in Tromsø 5 and 66 % (not so high) in Tromsø 6, and is well defined [113]. 
A cohort study with a participation rate above 80 % is considered more unlikely to produce a great 
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deal of selection bias [140]. Moreover, selection bias is less problematic in cohort studies as, at 
recruitment, the outcome of interest has yet to take place [140]. The high number of participants in 
paper II also reduces the likelihood of selection bias.  
Papers I and III are therefore more prone to selection bias than paper II. 
Information bias 
Information bias can be described as bias in the collection, analysis and interpretation of data [137].  
Misclassification was a central issue in the Tromsø Dementia Study (papers I and III). Cases were 
selected from the second Tromsø 6 visit because of low cognitive test scores. MCI was then 
appraised in the Tromsø Dementia Study based on Petersen’s original construct [141]. Cases with 
cerebral pathology such as cerebral strokes (not lacunar) and tumors on MRI were excluded. 
The resulting cases with MCI were considered to have probable prodromal sporadic LOAD, probable 
prodromal familial LOAD or to be intermediate. They might also have co-existing CSVD. However, 
cases could, for example, be in the prodromal stage of dementia with Lewy bodies, and not have MCI 
due to prodromal LOAD [142].  
Persons with MCI have an increased risk of dementia, most often due to AD which is most prevalent. 
However, MCI is a heterogenous condition. The majority develop dementia, but some revert to 
normal cognitive function and do not necessarily have an increased risk for dementia [143]. The 
proportion of MCI cases in the Tromsø Dementia Study with prodromal LOAD or CSVD is therefore 
uncertain.  
Existing biomarkers and cognitive tests can not adequately detect AD in preclinical and prodromal 
stages. There might therefore, for example, be controls with preclinical LOAD and preclinical 
dementia with Lewy bodies. In clinical studies and trials on MCI and AD, finding valid cases is 
challenging. PET amyloid imaging and CSF biomarkers are therefore applied to enrich samples 
[91,108]. This was not feasible in the Tromsø Dementia Study. However, the classification of cases 
into probable prodromal sporadic LOAD, probable prodromal familial LOAD and with or without 
parental LOAD, might function as enrichment in the latter groups.  
Questionnaires from the first and second Tromsø 4 and Tromsø 6 visits gathered information on 
education, alcohol usage and cardiovascular risk factors such as smoking, hypertension, diabetes, 
coronary disease and stroke. This information was susceptible to recall bias. However, studies have 
shown that self-reporting of chronic diseases have high validity [144-146]. In a study on the validity 
of self-reported stroke in the Tromsø Study, Engstad et al. found that self-reported stroke had a high 
positive predictive value and concluded that questionnaires could be used in epidemiological 
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research to assess a history of stroke [147]. Studies have shown that self-reported alcohol 
consumption can identify high alcohol consumers with a relatively high sensitivity and specificity, and 
that self-reported smoking has high validity in adults [148,149].  
A case control study should preferentially have more than one control for each case [150]. For 
logistical reasons, there were only 58 controls in the Tromsø Dementia Study, around half the 
number of cases. The low number of controls reduces the internal validity of the results in the 
Tromsø Dementia Study. 
Cases in the Tromsø Dementia Study had MCI or SMC, and controls were considered cognitively 
healthy. Cases and controls may therefore have differed in their abilities to recall past exposures. 
Recall bias is a concern especially in case-control studies [138]. Cases and controls answered 
questionnaires regarding past exposures in Tromsø 6, and in the Tromsø Dementia Study provided 
information on past exposures in interviews. Errors in recall of past exposures can bias the results of 
a study.  
The cases were, in paper I, classified into three groups. The classification was based on information 
on the dispersion of probable LOAD among biological relatives in their families obtained in interviews 
with cases and their companions (most often their spouses). Companions had been invited for 
verification and for collateral information, as information from persons with MCI might be unreliable. 
However, family memories usually diminish late in the course of AD. Nevertheless, there was a risk 
for misclassification due to erroneous information. 
In paper III, the cases with SMC could have been misclassified as they lacked MMSE scores from 
Tromsø 6. However, their mean MMSE score in the Tromsø Dementia Study was 0.8 points higher 
than cases with MCI and 1.2 points lower than controls. Moreover, SMC represents a more 
heterogenous condition than MCI, and can for example stem from anxiety and depression [55].  
NeuroQuant has been validated by comparisons with manually segmented volumetric 
measurements, and can detect differences in brain volumes between cognitively healthy older adults 
and persons with MCI [151,152]. NeuroQuant has also been shown to distinguish AD from non-
dementia in clinical practice [153]. Errors in NeuroQuant measurements are probably random and of 
limited impact. 
In paper II, ACR was calculated for all 1 577 participants by measuring urine albumin concentration 
and urine creatinine. Ultrasonography of the right internal carotid artery rendered measurements of 
IMT and TPA for all 1 577 participants. Errors in ACR, IMT and TPA measurements are probably 
40 
 
random and reduce the chances of finding significant associations, i.e. increase the chance of not 
rejecting a false null hypothesis.  
Confounding 
Confounding refers to a situation in which a non-causal association between a given exposure and an 
outcome is observed as a result of the influence of a third variable, which is designated a 
confounder. The confounder must be related to both the putative risk factor and the outcome. The 
confounder is responsible for all or part of the statistical association between the exposure and the 
outcome [138]. A confounder is an extraneous variable whose presence affects the variables being 
studied, so that the results do not reflect the actual relationship between the variables under study 
[154].  
In papers I-III, age is the most important confounder, as it is associated both with many exposure 
variables and with all outcome variables. To control for confounding, the participants were drawn 
from the same population. Moreover, in multiple regression, the analyses were adjusted for several 
other variables than the main exposure variables, to better estimate the associations of main 
interest. For example, in addition to major confounders such as age and sex, analyses were adjusted 
for education, smoking, alcohol intake, folic acid, cobalamin and eGFR. However, there might still be 
residual confounding not accounted for due to unknown confounders. 
In papers I and III (Tromsø Dementia Study), eligible controls were matched for sex and age. 
However, inadequate matching for age resulted in case groups that were significantly older than 
controls. In paper I, this applied to men in groups 2 and 3 and in paper III to the MCI group. 
Interaction differs from confounding. Interaction occurs when the effect of one exposure variable for 
an outcome depends on the level of one or more other exposure variables. The effect of one 
exposure becomes changed or modified, dependent on the level of another exposure. Interaction is 
therefore also known as effect modification [155]. To test for interactions, interaction terms 
(products of two exposures) were applied in the ANCOVA and multiple regression analyses. In paper 
I, there was an interaction between gender and groups 1-4 for tHcy. All analyses were therefore 
performed gender specific. In paper III, there was a borderline significant interaction between gender 
and probable parental LOAD for hippocampal volume. Additional multiple regression analysis 
stratified by gender and parental LOAD was therefore performed.  
External validity of the results in papers I-III 
External validity pertains to whether the results can be generalized. The data in papers I-III are 
selected from samples drawn from the Tromsø Study. If our study samples are representative of the 
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Tromsø 6 cohort, and the results have internal validity, then our study results might have external 
validity and apply beyond the Tromsø 6 cohort. 
In papers I and III, analyses were performed on small numbers of participants, and the number of 
controls was less than half the number of cases. This increases the probability of finding false 
associations, both positive and negative, and renders it uncertain whether the study samples are 
representative of the Tromsø 6 cohort. The probability that the results have internal and external 
validity is therefore lower. 
Paper II has many participants from a well defined population and, as it is not a case-control study, 
the probability of achieving internal and external validity is higher.  
 
Discussion of results 
Paper I 
In this cross sectional case-control study, ANCOVA was gender stratified as there was an interaction 
between gender and groups 1-4 for tHcy. 
In the original case group classification, group 4 represented probable prodromal familial LOAD, 
group 2 represented probable prodromal sporadic LOAD and group 3 represented an intermediate 
group. 
Unlike the other case groups, women with probable prodromal familial LOAD did not have 
significantly higher tHcy than controls. In men, all case groups had significantly higher tHcy than 
controls. Unlike men, women with probable prodromal LOAD differed significantly in the volumes of 
cerebral structures compared with controls and other case groups. 
Earlier studies and trials on tHcy and AD have shown equivocal results. For over 20 years it has been 
debated whether tHcy is a risk marker or a risk factor for AD [67]. Recently, an international expert 
group concluded in a consensus statement that elevated tHcy is a modifiable risk factor for 
development of cognitive decline, dementia, and AD in older persons [67]. tHcy appears to be a risk 
factor both for AD and CSVD [22]. Our results might help explain equivocal results in earlier studies 
on tHcy and risk of LOAD [67,156,157]. 
Women with probable prodromal familial LOAD did not have significantly higher tHcy than controls, 
including in the alternative classification of group 4, unlike the other case groups. Moreover, in the 
alternative classification, the differences in volumes of cerebral structures between women in group 
4 and women in groups 1-3 increased. Women with probable prodromal familial LOAD in particular 
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differed in hippocampal volume. Their mean hippocampal volume was smaller than in controls, in 
women with probable prodromal sporadic LOAD and in women in the intermediate group. Women 
with probable prodromal familial LOAD also differed in the volume of lateral ventricles. They had 
larger lateral ventricular volume than controls and women with probable prodromal sporadic LOAD.  
Ventricular enlargement is a convenient measure of disease progression, due to the high contrast 
between CSF and the surrounding brain tissue [99]. In a prospective study from 2008, Nestor et al. 
found that at baseline, ventricular volume was significantly larger in both AD subjects and MCI 
subjects compared to controls [97]. After six months, all groups had a significant increase in 
ventricular volume. The AD subjects had a significantly greater ventricular enlargement than both 
subjects with MCI and controls. Subjects with MCI also had a significantly greater rate of 
enlargement than controls. In contrast to our study, Nestor et al. measured the volumes of all four 
cerebral ventricles, did not classify MCI into probable prodromal sporadic and familial LOAD, and did 
not perform gender specific analyses. 
The gender difference in volumetry of cerebral structures in our study is consistent with earlier 
studies, which have shown gender differences [158]. Examples include a study of paternal and 
maternal transmission of familial LOAD, and a prospective study of AD and amnestic MCI [159-161]. 
It has been shown that the risk conferred for AD by being a first-degree relative of persons with AD, 
female or by having an ε4 allele is of similar magnitude [73]. Moreover, that having a first-degree 
family history of LOAD, especially when a parent is affected, is the most significant risk factor for 
developing LOAD [72]. Our volumetric findings particularly in women with MCI and probable parental 
LOAD, are consistent with this.  
The differences in cerebral volumetric findings between women with probable prodromal sporadic 
LOAD and women with probable prodromal familial LOAD suggest that sporadic and familial LOAD 
might differ in etiology and pathophysiology [4,7,72,73]. The different findings in women and men in 
the cerebral volumetry of cases with probable prodromal familial LOAD compared to controls and 
cases with probable prodromal sporadic LOAD, suggest that familial LOAD might have gender 
differences.  
In both genders in our sample, more than 65 % of the biological relatives with probable LOAD were 
women. This is similar to previous studies which suggest that maternal transmission of AD is more 
frequent than paternal transmission, and that having an AD-affected mother confers a greater risk 
than having an AD-affected father [162-164]. Likewise, Berti et al. found grey matter volume 
reductions in normal individuals with a maternal history of AD study, but not in normal individuals 
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with a paternal history of AD [159]. They concluded that maternal transmission might lead to a more 
increased risk for LOAD than paternal transmission.  
In a prospective study, Honea et al. found progressive regional atrophy, including of the medial 
temporal lobes, in cognitive normal adults with a maternal history of AD [161]. Among controls in our 
study, five female controls had mothers with probable LOAD and eight male controls had mothers 
with probable LOAD. Compared with the number of male and female controls, this constitutes an 
equal distribution of mothers with probable LOAD among male and female controls. If female 
controls had smaller hippocampus because of this, it would have become more difficult to distinguish 
cases from controls. However, this might be an explanation for not finding differences between male 
controls and cases. 
Many studies have found sex differences in AD. In 2015, the American Alzheimer’s Association 
convened experts to explore these differences [165,166]. They moved forward a research agenda to 
better understand the biological underpinnings of sex and gender related disparities of risk for AD. 
One of the areas they identified in which increased research was needed was the role of sex 
chromosomes on AD-like biological changes, using genome wide association studies (GWAS) and 
other techniques to more fully analyze the X and Y chromosomes.  
In a review from 2014 on sex and gender differences in AD, Mielke et al. concluded that prevalence 
and incidence of AD, brain structure and function and risk factors vary by sex and gender [167]. In 
future research on AD, they recommended carrying out sex and gender specific studies and trials.  
In a prospective study from 2015, Lin et al. found marked gender differences in progression of mild 
cognitive impairment over 8 years [168]. In MCI subjects, women declined at much higher rates than 
men. Consequently, they recommended gender specific research in AD. 
In a prospective study from 2010 on elderly subjects with MCI and AD and cognitively healthy 
controls, Hua et al. found significant age and sex differences in atrophic rates [169]. Brain atrophic 
rates were about 1 %-1.5 % faster in women than men. Atrophy was faster in younger than older 
subjects, and most prominently in mild cognitive impairment. 
In a prospective study from 2013 that measured the effects of age, ApoE ε4 and sex on brain 
atrophy, Holland et al. found that sex differences in atrophy rates were as large as differences 
associated with ApoE ε4 [170]. The study population consisted of cognitively healthy elderly, elderly 
with MCI and elderly with AD. In all stages, from healthy aging through AD, women had higher rates 
of brain atrophy than men, and the magnitude of the sex differences was at least as large as the 
magnitude of the ApoE ε4 effects. 
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In our study population, the distribution of ApoE genotypes were as follows: ε2/ε2 0.6 %, ε2/ε3 11.2 
%, ε2/ε4 1.9 %, ε3/ε3 50.9 %, ε3/ε4 30.4 % and ε4/ε4 5.0 %. The ApoE ε4 allele was prevalent, 37.3 % 
of participants being carriers of the ApoE ε4 allele. Among cases and controls, 35 % and 41 % had the 
ApoE ε4 allele, respectively. 
A Norwegian study from 2008 by Sando et al. found that among elderly persons with probable LOAD, 
the ApoE ε4 allele was present in 64.1 % of cases [77]. 
In women, group 2 (probable prodromal sporadic LOAD) had the lowest prevalence at 27 %. In men, 
group 3 (the intermediate group) had the lowest prevalence at 17 %. Prevalence in the other groups 
ranged from 33 % to 46 %. In women, the difference was largest between the groups for probable 
prodromal familial LOAD and probable prodromal sporadic LOAD. In the former group, 47 % had the 
ApoE ε4 allele, while 27 % of the latter group had the ApoE ε4 allele. This might explain why women 
with probable prodromal familial LOAD differed most in volumetry of cerebral structures in our 
study. 
Previous studies have shown associations between the ApoE ε4 allele and size of cerebral structures, 
also in cognitive intact adults [171-174]. A recent prospective study by Altmann et al. found that 
female carriers of the ApoE ε4 allele had a higher risk than male carriers of converting from healthy 
cognitive function to MCI, and from MCI to AD [175]. However, in our cross-sectional study, although 
the alternative classification led to enhanced differences in group 4 in women, the prevalence of the 
ApoE ε4 allele fell from 47 % to 38 %. Thus, the differences in group 4 can not be fully attributed to 
the prevalence of the ApoE ε4 allele.   
In both male and female control groups, many were carriers of the ApoE ε4 allele and many had 
parents with probable LOAD. In AD, presence of the ApoE ε4 allele is associated with increased rates 
of hippocampal loss [176]. It is conceived that MRI changes due to AD precede the onset of MCI [8]. 
As probable parental LOAD and the ApoE ε4 allele were prevalent, several controls might have 
preclinical LOAD. This would render it harder to find differences between cases and controls. As such, 
it strengthens our findings.  
The Norwegian study from 2008 by Sando et al. found that 26.4 % of cognitively normal elders were 
carriers of the ApoE ε4 allele [77]. Among our controls, 41 % were carriers of the ApoE ε4 allele. The 
reason for the high prevalence of the ApoE ε4 allele among our controls is unclear. One possible 
explanation is that invited controls who had biological relatives with LOAD were especially eager to 
attend the Tromsø Dementia Study.  
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There is insufficient knowledge on the prevalence of the ApoE ε4 allele among cognitive healthy 
adults and among adults with AD in Norway and other countries [77]. The ApoE ε4 allele and the 
ApoE ε3 allele are inversely correlated in Europe, with the ApoE ε4 allele being more prevalent in 
populations in Northern Europe than in Southern Europe [177].  The ApoE ε4 allele prevalence varies 
among AD patients by region and within each country, with the highest prevalence in northern 
Europe and the lowest in Asia and Southern Europe [178]. 
With the exception of tHcy, we found no differences in cardiovascular risk factors between groups. 
This is in line with earlier cross-sectional studies that have found no significant impact of 
cardiovascular risk factors on the risk of LOAD [156,179]. 
Paper II 
In multivariate linear regression, ACR and IMT measured in 1994 independently predicted processing 
speed (DST) in 2007. To our knowledge, there have been no previous prospective studies on 
cognitive function that apply internal carotid IMT and albuminuria as exposure variables 
simultaneously and therefore no studies which have shown that albuminuria and carotid IMT 
independently predict cognitive function. 
Higher ∆ACR was associated with lower processing speed and psychomotor tempo (FTT), while 
higher ∆IMT had a borderline association with lower psychomotor tempo. Substitution of IMT and 
∆IMT with TPA and ∆TPA yielded the same associations, except that higher ∆TPA independently was 
significantly associated with both lower processing speed and psychomotor tempo.  
These associations were for ACR levels substantially below the limits for microalbuminuria. This 
suggests that low-grade albuminuria has relevance for cognitive function. Earlier studies have shown 
that ACR levels below the usually defined cut-off levels for pathological albuminuria have 
independently predicted mortality [180]. 
Small vessel disease is considered a systemic disorder. Microalbuminuria might therefore reflect 
endothelial dysfunction in the cerebral microcirculation due to CSVD [181]. The brain and kidneys 
share hemodynamic properties, including low resistance and high circulatory flow [84]. A systematic 
review and meta-analysis from 2017 by Georgakis et al. found that albuminuria was independently 
associated with cognitive impairment, dementia and cognitive decline [84]. It also showed that 
albuminuria was associated with diffuse neuropsychological defects similar to the profile of vascular 
cognitive impairment, the greatest impairment being in the domain of processing speed [182]. Paper 
II was included as one of 32 eligible studies in this systematic review and meta-analysis. 
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Georgakis et al. found, in another recent systematic review and meta-analysis, that albuminuria was 
independently associated with CSVD, as measured on MRI by WMH, lacunar infarcts, cerebral 
microbleeds and enlarged perivascular spaces [183]. These associations between microalbuminura 
and CSVD lend support to the associations between microalbuminuria and cognitive function. 
Our results are in line with the findings on cognitive aging by Baudoin et al. [184]. They found that 
the DST combined executive processes and perceptual speed, that executive functions are a 
significant mediator of age-related differences in memory, DST performance being the best 
predictor. Our results suggest that endothelial dysfunction and atherosclerosis independently 
contribute to the impairment in several cognitive domains that is associated with normal aging [185]. 
Also, our results add weight to studies which have shown that impaired executive function is present 
in early stages of VCI and VaD caused by CSVD [86,186]. 
Higher carotid IMT and TPA are risk factors for stroke and subsequent cognitive impairment [89]. 
Studies suggest that subclinical carotid atherosclerosis without stroke may also be an independent 
risk factor for cognitive decline and dementia [89]. However, study results have been equivocal, and 
it has not been ascertained that higher IMT and TPA are predictors of cognitive impairment 
[89,187,188]. In a recent cross-sectional study, Wang et al. found an association between carotid IMT 
and cognitive function measured with the MMSE, among stroke free middle-aged and older adults in 
a Chinese population [189]. In a prospective study, Zhong et al. assessed the impact of carotid 
atherosclerosis on 10-year changes in cognitive function [190]. Higher IMT was associated with an 
increased risk of cognitive impairment. However, higher IMT was not associated with lower DST 
scores 10 years later.  
In ANCOVA, women with IMT at or above the median had a significant linear trend of a lower DST 
score for increasing ACR. Also, women with IMT below the median in the highest ACR quartile (ACR 
quartile 4) had significantly lower DST scores than corresponding women in the lower ACR quartiles 
(ACR quartiles 1-3). The reasons for these findings are unclear. One explanation might be that there 
is a closer connection between endothelial dysfunction and atherosclerosis in women than in men.  
In our study, smoking independently predicted lower DST and FTT scores. Earlier prospective studies 
have also shown an association between smoking and cognitive impairment [191]. In a recent 
prospective study, Sabia et al. showed that, compared with never smokers, middle-aged male 
smokers experienced faster cognitive decline especially in executive function, but also in global 
cognition [192]. One reason for the gender difference in the study by Sabia et al., might be that male 
smokers smoked significantly more than female smokers. Our study results open up the possibility 
that smoking impairs motor speed, psychomotor speed and executive function independent of 
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endothelial dysfunction and atherosclerosis. To our knowledge, it has not been shown previously 
that albuminuria, internal carotid atherosclerosis and smoking independently predict psychomotor 
and executive function. 
Previous studies have found equivocal associations between eGFR and cognitive function among 
persons from a general population [88,193,194]. In our study, higher eGFR was independently 
associated with lower DST score. One possible reason is that in our sample, which is from a general 
population, the mean eGFR was normal and had a very small standard deviation, and that the effect 
size (β value) in the multiple regression analysis was close to zero. Moreover, estimations of GFR 
creatinine-based equations do not perfectly reflect true GFR, especially when GFR is normal or near-
normal. 
Paper III 
Volumes of hippocampus and cerebral structures served as surrogate markers for AD. However, 
other neurodegenerative diseases, CSVD and aging also lead to atrophy of hippocampus and other 
cerebral structures [195]. Exposure variables were cardiovascular and genetic risk factors.  
One aim was to assess whether the fully automated software NeuroQuant could distinguish 
sufficiently between cognitive healthy controls on the one side and subjects with SMC or MCI on the 
other, to be useful in the clinical routine. 
In a previous Norwegian study from a memory clinic, fully automated volumetry using NeuroQuant 
distinguished AD from MCI and subjective cognitive impairment, but did not distinguish between 
different kinds of dementia [104]. Receiver operating characteristic analyses were performed. The 
calculated area under the curve in AD compared to MCI and subjective cognitive impairment was 
0.80 for hippocampus and 0.73 for the lateral ventricles. They concluded that NeuroQuant provided 
support for the results of other clinical investigations, but could not be used alone to distinguish 
between persons with AD and persons without dementia. 
In a recent study on the same population by Persson et al., NeuroQuant was compared to visual 
evaluation of medial temporal lobe atrophy using the Scheltens scale [105]. They found that 
NeuroQuant and visual evaluation of medial temporal lobe atrophy correlated well, and had 
equivalent discriminatory power and accuracy in distinguishing AD patients from MCI and subjective 
cognitive impairment patients. 
In our study using cognitive healthy controls, the calculated area under the curve in SMC and MCI 
compared to controls was less than 0.68 for all measured volumes of intracranial structures. 
Accordingly, our results imply that NeuroQuant is not useful in clinical practice to distinguish 
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between cognitive healthy persons and persons with MCI or SMC. Nevertheless, in the clinical 
routine, fully automated volumetry can be repeated to assess whether the atrophy rate is abnormal, 
and be useful with other biomarkers in diagnosing preclinical LOAD [151,196-198]. 
In a recent study by Tanpitukpongse et al., receiver operating characteristic curves assessed the 
prognostic efficacy of NeuroQuant and another fully automated software package, NeuroReader, to 
predict conversion of MCI to AD [199]. They found that hippocampal volume was the best single 
predictor of conversion of MCI to AD. 
This is consistent with our findings in the Tromsø Dementia Study (papers I and III). We found that 
the most significant differences between groups were for hippocampal volume, and that exposure 
variables of interest particularly had associations with hippocampal volume. Hippocampal atrophy is 
an early finding in AD, and as our cases had SMC and MCI, associations with hippocampal volume 
were most likely [99,200].  
In ANCOVA, MR volumetry distinguished persons with SMC and MCI from controls. The MCI group 
was, however, significantly older than controls, which can not be fully adjusted for in linear 
regression analysis. However, the SMC group was not significantly older than controls, but differed 
significantly from controls in volumetric measurements. This increases the probability that the MCI 
group also differed significantly from controls. Volumetry of the hippocampus and the lateral 
ventricles in particular distinguished the SMC and MCI groups from controls.  
Compared to controls, the volumes of the cerebral cortex and cerebrum were smaller in the MCI 
group. In contrast to the medial temporal lobe, recognizable atrophy of these structures occurs later 
in the disease course of AD [171]. However, the MCI group was significantly older than controls and 
the validity of these findings is therefore uncertain.  
Amygdala atrophy is also an early finding in AD. Findings have, however, been less consistent than 
for hippocampal atrophy [201]. In two large, independent samples of very mild and mild AD patients, 
Poulin et al. found that amygdala atrophy was comparable to hippocampal atrophy using fully 
automated volumetry with the software package Freesurfer [201].                                                                                   
In our sample, amygdala was smaller only in persons with MCI. This is in line with inconsistent 
findings in previous studies. A reason might be that the boundaries of hippocampus are easier to 
recognize both visually and with fully automated software [99]. The MCI group was significantly older 
than the control group and the validity of this finding is therefore uncertain. This also applies to the 
volume of white matter hyperintensities (WMH) which in our study was larger only in the MCI group. 
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WMH are considered the most common marker of small vessel disease in the brain, and are 
associated with an increased risk of developing AD [202,203]. However, studies on the clinical 
significance of WMH in patients with MCI and AD have reported mixed results [202].  
Associations between cardiovascular and genetic risk factors on the one hand, and volumes of 
cerebral structures on the other were tested in multiple regression analysis of all participants.                 
tHcy was the risk factor with most associations with volumes of cerebral structures. Higher tHcy was 
associated with less hippocampal volume, less amygdalar volume, less volume of cerebral cortex, less 
cerebral volume and larger lateral ventricular volume. 
Higher tHcy level has been associated with brain atrophy in several studies [204-206]. Elevated tHcy 
is associated with hippocampal atrophy in cognitively normal elderly people and with faster rates of 
medial temporal lobe atrophy in AD [207].  B-vitamin treatment in persons with high tHcy has been 
shown to reduce cerebral atrophy in gray matter regions specifically vulnerable to AD [206]. 
In multiple regression analysis, probable parental LOAD, presence of the ApoE ε4 allele, lower total 
cholesterol, higher tHcy and higher eGFR were independently associated with smaller hippocampal 
volume. Stratified by gender, the associations were still significant in women, but not in men. In 
women, the association between probable parental LOAD and hippocampal volume became more 
significant. The reasons behind these independent associations are unclear. One explanation might 
be that sporadic and familial LOAD have different etiologies [41]. Another explanation is that these 
associations are spurious due to the low number of cases and controls. The difference between men 
and women may be due to sex differences in the etiology and pathophysiology of LOAD [167,208]. 
Our results might also suggest a difference between men and women with probable parental LOAD 
in acquiring LOAD, and underline the importance of performing sex-specific analyses in studies on 
LOAD [75].  
Okonkwo et al. carried out a prospective study of cognitively healthy middle-aged adults who had 
one or two parents with LOAD. Over a 4-year interval, these cognitively healthy middle-aged (mean 
age at baseline was 54 years) adults exhibited significant atrophy in the posterior hippocampi in the 
absence of measurable cognitive changes [209]. This was regardless of maternal or paternal AD, and 
suggests that cerebral atrophy in AD starts earlier than presumed. 
Lampert et al. carried out a prospective study on elder (mean age 80 years) subjects with MCI, who 
either had a parent or sibling with AD, or did not have a family history of AD [210]. Subjects with a 
family history of AD had greater atrophy of the amygdala, hippocampus and cortical gray matter 
compared to subjects without a family history of AD. However, when the ApoE ε4 allele was added as 
a covariate, the family history effects of AD were no longer significant.                                                                   
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This differs from our findings. One explanation might be that Lampert et al., in contrast to Okonkwo 
et al. and ourselves, mixed together cases with parental AD and cases with AD in a sibling. Parental 
LOAD represents a greater risk for LOAD than LOAD in a sibling [73]. Another explanation is that the 
participants in the study by Lampert et al. were considerably older than the participants in the study 
by Okongwo et al. and in our study. Okongwo et al. found no significant main effects of being a 
carrier of the ApoE ε4 allele in their prospective study. 
Higher total cholesterol was in our study independently associated with larger volumes of 
hippocampus, amygdala and cerebrum and smaller volumes of the lateral ventricles. We have no 
clear explanation for these associations, which could be spurious. 
Cholesterol is a lipid that is essential for cell membrane structure and function [211]. The ApoE ε4 
allele confers the greatest risk for developing familial and sporadic LOAD, most likely by reducing 
cholesterol efflux from neuronal cells and astrocytes, and by binding and depositing Aβ [212]. 
Cholesterol metabolism and trafficking might thus be important for LOAD susceptibility. ApoE is 
essential for normal lipid homeostasis in the brain, and ApoE ε4 is less efficient than ApoE ε3 in 
delivering cholesterol to neurons [18,213].                                                                                                       
Cholesterol might be a risk factor for both cardiovascular disease and AD. Studies and trials on 
cholesterol and AD have, however, rendered equivocal results [214,215]. High total cholesterol level 
at midlife has been associated with an increased risk of developing AD. Conversely, a high total 
cholesterol level between age 70 and 79 years has been found to reduce the risk of developing 
dementia between age 79 and 88 years.                                                                                                                                               
In a cross-sectional study of participants free of stroke and cognitive impairment, and aged ≥60 
years, Qiu et al. found that high total cholesterol and diabetes were significantly or marginally 
associated with smaller hippocampus and entorhinal cortex in men [216].  
Previous studies have shown that the presence of the ApoE ε4 allele is associated with hippocampal 
atrophy, amygdalar atrophy, entorhinal cortex atrophy, increased brain atrophy and increased WMH 
volumes [217-219]. In our sample, we only found an association between the ApoE ε4 allele and 
smaller hippocampal volume. The reason for this is probably that our study was of SMC and MCI, and 
the likelihood for finding atrophy of cerebral structures occurring later in the disease course of AD 
was less.  
In our sample, higher eGFR was associated with smaller volumes of hippocampus, cerebrum and 
cerebral cortex [220]. We have no explanations for these associations which could be spurious. 
In a recent study on a cognitively normal population, Cho et al. found no associations between eGFR 
and cerebral cortical atrophy [221]. In a review and meta-analysis by Derckers et al. on dementia risk 
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in renal dysfunction, they found no clear association between eGFR levels and cognitive decline or 
dementia risk [220].  
In our sample, the ApoE ε4 allele was present in 41 % of controls, 52 % of cases with SMC and 34 % 
of cases with MCI. The prevalence of the ApoE ε4 allele in the general population is approximately 15 
% and approximately 40 % in patients with AD [212]. However, these estimates vary, also with 
latitude. Another estimate is that approximately 65-75 % of patients with AD carry the ε4 allele [222]. 
The APOE allele distribution seems to depend on ethnicity and varies with latitude, higher ε4 
frequencies being more common close to the equator and in the northern polar region. 
In a Norwegian study by Sando et al. of 376 AD patients and 561 healthy controls, 26.4 % of the 
controls and 64.1 % of the AD patients were carriers of the ApoE ε4 allele [77].                                                                        
A reason for the high prevalence in our control group might be that among invited controls, persons 
with LOAD in their family consented more readily. The same reason may also apply to the even 
higher prevalence in the SMC group, and increases the probability that cases in the SMC group had 
prodromal LOAD.  
 
Conclusions and implications 
Paper I 
In contrast to women and men with probable prodromal sporadic LOAD, and men with probable 
prodromal familial LOAD, women with probable prodromal familial LOAD did not have significantly 
elevated tHcy compared to controls. 
Furthermore, women with MCI and probable prodromal familial LOAD differed significantly from 
controls and from women with probable prodromal sporadic LOAD in fully automated volumetry of 
hippocampus and lateral ventricles. Similar differences were not found in men. 
Previous studies have found gender differences in volumes of cerebral structures in cognitive 
impairment. However, to our knowledge, previous studies have not shown the results just 
mentioned. 
The implications of our findings are unclear, and open up for many explanations. For example that 
sporadic LOAD and familial LOAD have different etiologies and pathophysiologies, that women have 
a higher risk of inheriting AD and that tHcy is not a risk factor for familial LOAD in women. 
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To our knowledge, previous studies on MCI, prodromal AD and MR volumetry have not distinguished 
between probable prodromal sporadic LOAD and probable prodromal familial LOAD. By doing so, we 
could look for differences between them. Our results suggest that making this distinction is relevant. 
Similar studies should be carried out to check the validity of our results. These studies should have a 
markedly larger sample size (both controls and cases) to achieve higher statistical power. 
Preferably, PET amyloid imaging, quantification of Aβ42, p-tau and t-tau in CSF should be applied for 
enrichment of cases.                                                                                                                                                                    
If our results are replicated, their validity is increased. Further research is then warranted to clarify 
implications. 
Paper II  
Our findings suggest that low-grade albuminuria, carotid atherosclerosis and smoking independently 
predicts impaired psychomotor tempo and executive function in a general population.  
To our knowledge, it has not previously been shown that these risk factors are independently 
associated with cognitive function.  
Our findings are consistent with previous studies that have shown associations between albuminuria, 
smoking and carotid atherosclerosis on the one hand, but not for all independently, and cognitive 
function on the other. 
Further studies should be carried out to elucidate the associations between albuminuria and carotid 
atherosclerosis on the one side, and cognitive function on the other. For example, to assess whether 
these also reflect normal cognitive aging due to an aging cerebral vasculature. 
Paper III 
Our main finding was that probable parental LOAD, the Apo ε4 allele, higher tHcy and higher eGFR 
were independently associated with smaller hippocampal volume. This finding was particularly for 
women. To our knowledge, this has not been shown in earlier studies.  
Our findings suggest that research on AD should differentiate between sporadic LOAD and familial 
LOAD, and also between genders, to find underlying disease mechanisms and etiologies.  
Similar studies with more participants should be carried out to see whether our findings are 
replicated. PET amyloid imaging and quantification of Aβ42, p-tau and t-tau in CSF should preferably 
be applied for enrichment of cases.   
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Verken god eller dårlig
Dårlig 
Meget dårlig
2 Hvordan synes du at helsen din er sammenlignet 










Angina pectoris (hjertekrampe) .......................
Hjerneslag/hjerneblødning ...........................










4 Har du langvarige eller stadig tilbakevendende 
smerter som har vart i 3 måneder eller mer?
Ja Nei
5 Hvor ofte har du vært plaget av søvnløshet de siste 
12 måneder? 
Aldri, eller noen få ganger
1-3 ganger i måneden
Omtrent 1 gang i uken
Mer enn 1 gang i uken
6 Under fi nner du en liste over ulike problemer. 
Har du opplevd noe av dette den siste uken 









Plutselig frykt uten grunn .......
Føler deg redd eller 
engstelig ................................................
Matthet eller svimmelhet ......
Føler deg anspent eller 
oppjaget ................................................
Lett for å klandre deg selv ....
Søvnproblemer ................................
Nedtrykt, tungsindig ..................
Følelse av å være unyttig, 
lite verd ..................................................
Følelse av at alt er et slit .........
Følelse av håpløshet 
mht. framtida ...................................
7 Har du i løpet av de siste 12 måneder vært hos: 
Hvis JA; Hvor mange ganger?








(homøopat, akupunktør, fotsoneterapeut, natur-
medisiner, håndspålegger, healer, synsk el.l) .....
Tannlege/tannpleier ............................................
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Du kan ikke bruke komma, bruk blokkbokstaver.
2007 – 2008 KONFIDENSIELT
9 Har du gjennomgått noen form for operasjon i løpet 
av de siste 3 årene?
Ja Nei
8 Har du i løpet av de siste 12 måneder vært på sykehus? 
Ja Nei Ant ggr
Innlagt på sykehus ................................................
Konsultasjon ved sykehus uten innleggelse;
Ved psykiatrisk poliklinikk ..................
Ved annen sykehuspoliklinikk ........
BRUK AV HELSETJENESTER
HELSE OG SYKDOMMER




10 Bruker du, eller har du brukt, noen av følgende 






Medisin mot høyt blodtrykk ...
Kolesterolsenkende medisin ....
Medisin mot hjertesykdom ....
Vanndrivende medisin ................






11 Hvor ofte har du i løpet av de siste 4 ukene brukt 



















12 Skriv ned alle medisiner – både de med og uten 
resept – som du har brukt regelmessig i siste 4 ukers 
periode. (Ikke regn med vitaminer, mineraler, urter, 
naturmedisin, andre kosttilskudd etc.)
VED FRAMMØTE vil du bli spurt om du har brukt 
antibiotika eller smertestillende medisiner de siste 
24 timene. Om du har det, vil vi be om at du oppgir 
preparat, styrke, dose og tidspunkt
13 Hvem bor du sammen med? (Sett kryss for hvert 
spørsmål og angi antall) 
Ja Nei Antall
Ektefelle/samboer .............................................
Andre personer over 18 år ........................
Personer under 18 år ......................................
14 Kryss av for de slektninger som har eller har hatt
Foreldre Barn Søsken
Hjerteinfarkt ..............................................
Hjerteinfarkt før fylte 60 år .........
Angina pectoris (hjertekrampe) ......
Hjerneslag/hjerneblødning ..........







15 Har du nok venner som kan gi deg hjelp 
når du trenger det?
Ja Nei
16 Har du nok venner som du kan snakke fortrolig med?
Ja Nei
17 Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som for eksempel syklubb, idrettslag, politiske lag, 
religiøse eller andre foreninger?
Aldri, eller noen få ganger i året
1-2 ganger i måneden
Omtrent 1 gang i uken
Mer enn en gang i uken
ARBEID, TRYGD OG INNTEKT
18 Hva er din høyeste fullførte utdanning? 
(Sett ett kryss)
Grunnskole, framhaldsskole eller folkehøyskole
Yrkesfaglig videregående, yrkesskole eller realskole 
Allmennfaglig videregående skole eller gymnas
Høyskole eller universitet, mindre enn 4 år
Høyskole eller universitet, 4 år eller mer
FAMILIE OG VENNERBRUK AV MEDISINER
Får du ikke plass til alle medisiner, bruk eget ark.
25 Hvor ofte driver du mosjon? (Med mosjon mener vi 
at du f.eks går en tur, går på ski, svømmer eller driver 
trening/idrett)
Aldri
Sjeldnere enn en gang i uken
En gang i uken
2-3 ganger i uken
omtrent hver dag
36 Hvor mange år til sammen har du røykt daglig?
Antall år
35 Hvor gammel var du da du begynte å røyke daglig?
Antall år
22 Arbeider du utendørs minst 25 % av tiden, eller i 
lokaler med lav temperatur, som for eksempel 
lager-/industrihaller?
Ja Nei
23 Hvis du er i lønnet eller ulønnet arbeid, hvordan vil 
du beskrive arbeidet ditt?
For det meste stillesittende arbeid
(f.eks. skrivebordsarbeid, montering)
Arbeid som krever at du går mye
(f.eks ekspeditørarbeid, lett industriarbeid, undervisning)
Arbeid der du går og løfter mye
(f.eks postbud, pleier, bygningsarbeider)
Tungt kroppsarbeid
24 Angi bevegelse og kroppslig anstrengelse i din 
fritid. Hvis aktiviteten varierer meget f eks mellom 
sommer og vinter, så ta et gjennomsnitt. Spørsmålet 
gjelder bare det siste året. (Sett kryss i den ruta som 
passer best)
Leser, ser på fjernsyn eller annen stillesittende 
beskjeftigelse
Spaserer, sykler eller beveger deg på annen måte 
minst 4 timer i uken (her skal du også regne med gang 
eller sykling til arbeidsstedet, søndagsturer med mer)
Driver mosjonsidrett, tyngre hagearbeid, snømåking 
e.l. (merk at aktiviteten skal vare minst 4 timer i uka)
Trener hardt eller driver konkurranseidrett 
regelmessig og fl ere ganger i uka
26  Hvor hardt mosjonerer du da i gjennomsnitt?
Tar det rolig uten å bli andpusten eller svett.
Tar det så hardt at jeg blir andpusten og svett
Tar meg nesten helt ut
29 Hvor mange enheter alkohol (en øl, et glass vin, eller 
en drink) tar du vanligvis når du drikker?
1-2 5-6 10 eller fl ere
3-4 7-9
32 Har du røykt/røyker du daglig?
Ja, nå Ja, tidligere Aldri
27 Hvor lenge holder du på hver gang i gjennomsnitt ?
Mindre enn 15 minutter 30 minutter – 1 time
15-29 minutter Mer enn 1 time






daglig eller nesten daglig
28 Hvor ofte drikker du alkohol? 
Aldri
Månedlig eller sjeldnere
2-4 ganger hver måned
2-3 ganger pr. uke
4 eller fl ere ganger pr.uke
21 Hvor høy var husholdningens samlede bruttoinntekt 
siste år? Ta med alle inntekter fra arbeid, trygder, 
sosialhjelp og lignende.
Under 125 000 kr 401 000-550 000 kr
125 000-200 000 kr 551 000-700 000 kr
201 000-300 000 kr 701 000 -850 000 kr 
301 000-400 000 kr Over 850 000 kr
34 Hvis du røyker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanlig-
vis daglig?
Antall sigaretter
33 Hvis du har røykt daglig tidligere, hvor lenge er det 
siden du sluttet?
Antall år 
31 Røyker du av og til, men ikke daglig?
Ja Nei
20 Mottar du noen av følgende ytelser?








37 Bruker du, eller har du brukt, snus eller skrå?
Nei, aldri Ja, av og til
Ja, men jeg har sluttet Ja, daglig
FYSISK AKTIVITET
ALKOHOL OG TOBAKK
48 Hvis du har født, fyll ut for hvert barn: fødselsår og 
vekt samt hvor mange måneder du ammet. 
(Angi så godt som du kan)









39 Hvor mange enheter frukt og grønnsaker spiser du i 
gjennomsnitt per dag? (Med enhet menes f.eks. en 
frukt, glass juice, potet, porsjon grønnsaker)
Antall enheter
38 Spiser du vanligvis frokost hver dag?
Ja Nei
40 Hvor mange ganger i uken spiser du varm middag? 
Antall
42 Hvor mye drikker du vanligvis av følgende? 



















44 Hvor ofte spiser du vanligvis fi skelever? 
(For eksempel i mølje)
Sjelden/aldri 1-3 g i året 4-6 g i året























45 Bruker du følgende kosttilskudd?
Daglig Iblant Nei
Tran, trankapsler .....................................................
Omega 3 kapsler (fi skeolje,selolje) ............
Kalktabletter ............................................................
47 Hvor mange barn har du født?
Antall
49 Har du i forbindelse med svangerskap hatt for høyt 
blodtrykk?
Ja Nei
52 Hvis Ja, i hvilket svangerskap?
Første Senere
53 Ble noen av disse barna født mer enn en måned for 
tidlig (før termin) pga. svangerskapsforgiftning?
Ja Nei
55 Hvor gammel var du da du fi kk menstruasjon 
første gang?
Antall år
51 Har du i forbindelse med svangerskap hatt protein 
(eggehvite) i urinen?
Ja Nei
50 Hvis Ja, i hvilket svangerskap? 
Første Senere
54 Hvis Ja, hvilke(t) barn
Barn 1 Barn 2 Barn 3 Barn 4 Barn 5 Barn 6
43 Hvor mange kopper kaffe og te drikker du daglig?






56 Bruker du for tiden reseptpliktige legemidler som 
påvirker menstruasjonen?
P-pille, hormonspiral eller lignende ....... Ja Nei
Hormonpreparat for overgangs-
alderen ............................................................................. Ja Nei
46 Er du gravid nå?
Ja Nei Usikker
VED FRAMMØTE vil du få utfyllende spørsmål om 
menstruasjon og eventuell bruk av hormoner. Skriv 
gjerne ned på et papir navn på hormonpreparater 
du har brukt, og ta det med deg. Du vil også bli 
spurt om din menstruasjon har opphørt og even-
tuelt når og hvorfor.
41 Hvor ofte spiser du vanligvis disse matvarene?













Kjøtt (ikke kvernet) ................
Kvernet kjøtt 
(pølser, hamburger o.l) ...........
Grønnsaker, frukt, bær ..
Mager fi sk ...............................
Feit fi sk .......................................
(f.eks.laks, ørret, makrell, sild, kveite,uer)
KOSTHOLD SPØRSMÅL TIL KVINNER
- en del av Tromsøundersøkelsen
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1.6 For at du skal kunne vise oss hvor god eller 
dårlig din helsetilstand er, har vi laget en 
skala (nesten som et termometer), hvor den 
beste helsetilstanden du kan tenke deg er 
markert med 100 og den dårligste med 0. 
Vi ber om at du viser din helsetilstand ved 
å trekke ei linje fra boksen nedenfor til det 



















1. BESKRIVELSE AV DIN HELSETILSTAND
Vis hvilke utsagn som passer best på din 
helsetilstand ved å sette ett kryss i en av 
rutene utenfor hver av de fem gruppene 
nedenfor:
1.3 Vanlige gjøremål (f.eks. arbeid, studier, 
husarbeid, familie- eller fritidsaktiviteter)
Jeg har ingen problemer med å utføre 
mine vanlige gjøremål
Jeg har litt problemer med å utføre mine 
vanlige gjøremål
Jeg er ute av stand til å utføre mine 
vanlige gjøremål
1.4 Smerte og ubehag
Jeg har verken smerte eller ubehag
Jeg har moderat smerte eller ubehag
Jeg har sterk smerte eller ubehag
1.1 Gange
Jeg har ingen problemer med å gå 
omkring
Jeg har litt problemer med å gå omkring
Jeg er sengeliggende
1.2 Personlig stell
Jeg har ingen problemer med personlig stell
Jeg har litt problemer med å vaske meg 
eller kle meg
Jeg er ute av stand til å vaske meg eller 
kle meg 
1.5 Angst og depresjon
Jeg er verken engstelig eller deprimert
Jeg er noe engstelig eller deprimert
Jeg er svært engstelig eller deprimert
10000
4
2.1 Hvor bodde du da du fylte 1 år?
I Tromsø (med dagens kommunegrenser)
I Troms, men ikke i Tromsø 
I Finnmark fylke
I Nordland fylke
Annet sted i Norge
I utlandet
2. OPPVEKST OG TILHØRIGHET




2.2 Hvordan var de økonomiske forhold i 





2.5 Hva var/er den høyeste fullførte utdanning til dine foreldre og din ektefelle/samboer? 




Grunnskole 7-10 år, framhaldsskole eller folkehøyskole ...........
Yrkesfaglig videregående, yrkesskole eller realskole  ....................
Allmennfaglig videregående skole eller gymnas .................................
Høyskole eller universitet (mindre enn 4 år) ............................................
Høyskole eller universitet (4 år eller mer) ...................................................
2.4 Lever din mor?
Ja Nei
Hvis NEI: alder ved død ..........................
Lever din far?
Ja Nei
Hvis NEI: alder ved død ..........................
2.6 Hva regner du deg selv som? (Kryss av for 











3.4 Jeg opplever at yrket mitt har følgende status i samfunnet: (dersom du ikke er i arbeid nå, tenk 
på hvilken status du opplevde av yrket du hadde sist) 
Meget høy sosial status




3.1 Nedenfor står tre utsagn om tilfredshet med livet som et hele. Vis hvor enig eller uenig du er i hver 
av de tre påstandene ved å sette ett kryss under det tallet som du synes stemmer best for deg




1 2 3 4 5 6 7
På de fl este måter er livet mitt nær idealet mitt ..............................................
Mine livsforhold er utmerkede ............................................................................................
Jeg er tilfreds med livet mitt ...................................................................................................
3.2 Nedenfor står to utsagn om syn på egen helse. Vis hvor enig eller uenig du er i hver av 
påstandene ved å sette kryss under det tallet som du synes stemmer best for deg




1 2 3 4 5 6 7
Jeg ser lyst på min framtidige helse ...............................................................................
Ved å leve sunt kan jeg forhindre alvorlige sykdommer ........................
3. TRIVSEL OG LIVSFORHLD
3.3 Nedenfor ber vi deg svare på noen spørsmål om forhold ved din arbeidssituasjon. Dersom du 
ikke er i arbeid nå, tenk tilbake på den jobben du hadde sist






Nei, så godt 
som aldri
Synes du at arbeidet ditt er for belastende, fysisk eller 
følelsesmessig? ...............................................................................................................
Blir du mobbet eller trakassert på arbeidsplassen din? ....
Har du tilstrekkelig innfl ytelse på når og hvordan du 
skal utføre arbeidet ditt? ....................................................................................
Blir du rettferdig behandlet på arbeidsplassen din? ............








Blitt plaget psykisk, eller truet med vold  ................................
Blitt slått, sparket eller utsatt for annen type vold ........
Noen i nær familie har brukt rusmidler på en slik 
måte at dette har vært til bekymring for deg .....................
Dersom du har opplevd noen av disse forholdene, hvor mye plages du av dette nå?
Ingen plager Noen plager Store plager 
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4.01 Har du i løpet av den siste måneden følt deg 
syk eller hatt en skade?
Ja Nei
4. SYKDOMMER OG PLAGER
Hvis JA: har du i den samme perioden? 




Vært innlagt i sykehus
Vært hos alternativ behandler 
(kiropraktor, homøopat eller lignende)
Tok ikke kontakt med hjelpeapparatet
4.03 Blir du tungpustet i følgende situasjoner? 
(sett ett kryss for hvert spørsmål)
Ja Nei
Når du går hurtig på fl atmark eller 
svak oppoverbakke ....................................................
Når du spaserer i rolig tempo på 
fl atmark ...................................................................................
Når du vasker deg eller kler på deg ........
Når du er i hvile .............................................................
4.04 Hoster du omtrent daglig i perioder av året?
Ja Nei
Hvis JA: Er hosten vanligvis ledsaget av oppspytt?
Ja Nei
Har du hatt slik hoste så lenge som i en 3 
måneders periode i begge de to siste årene?
Ja Nei
4.02 Har du merket anfall med plutselig endring i 
pulsen eller hjerterytmen siste året?
Ja Nei
4.06 Nedenfor ber vi deg besvare noen spørsmål 
om din hukommelse: (sett ett kryss for hvert 
spørsmål)
Ja Nei
Synes du at din hukommelse har 
blitt dårligere? ..................................................................
Glemmer du ofte hvor du har lagt 
tingene dine? ....................................................................
Har du problemer med å fi nne 
vanlige ord i en samtale? ....................................
Har du fått problemer med daglige 
gjøremål som du mestret tidligere?.........
Har du vært undersøkt for 
sviktende hukommelse? .......................................
Hvis JA på minst ett av de fi re spørsmålene 
ovenfor: Er det et problem i hverdagen?
Ja Nei
4.05 Hvor ofte er du plaget av søvnløshet? 
(sett ett kryss)
Aldri
1-3 ganger i måneden
Omtrent 1 gang i uka
Mer enn 1 gang i uka
Hvis du er plaget av søvnløshet månedlig 
eller oftere, når på året er du mest plaget? 





4.07 Har du i løpet av det siste året vært plaget med smerter og/eller stivhet i muskler og ledd som 
har vart i minst 3 måneder sammenhengende? (sett ett kryss i hver linje)
Ikke plaget En del plaget Sterkt plaget
Nakke, skuldre .........................................................................................................
Armer, hender ..........................................................................................................
Øvre del av ryggen ............................................................................................
Korsryggen ..................................................................................................................
Hofter, ben, føtter ...............................................................................................
Andre steder ..............................................................................................................
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4.08 Har du vært plaget med smerter og/eller stivhet i muskler og ledd i løpet av de siste 2 ukene?
(sett ett kryss i hver linje)
Ikke plaget En del plaget Sterkt plaget
Nakke, skuldre .........................................................................................................
Armer, hender ..........................................................................................................
Øvre del av ryggen ............................................................................................
Korsryggen ..................................................................................................................
Hofter, ben, føtter ...............................................................................................
Andre steder ..............................................................................................................
4.09 Har du noen gang hatt: Alder 
siste gangJa Nei
Brudd i håndledd/underarm? .........................................................................................................................................
Lårhalsbrudd? ....................................................................................................................................................................................
4.11 Har du opplevd ufrivillig barnløshet i mer 
enn 1 år?
Ja Nei
Hvis JA, skyldtes dette: Vet 
ikkeJa Nei
Forhold hos deg selv? ..............
Forhold hos partneren? ..........





4.13 Til kvinnen: Har du spontanabortert?
Ja Nei Vet ikke
Hvis JA, antall ganger ..............................
4.17 Bruker du glutenfri diett?
Ja Nei
4.19 Har du fått stilt diagnosen dematitis 
herpetiformis (HD)?
Ja Nei
4.18 Har du fått stilt diagnosen cøliaki i en vevs-
prøve fra tynntarmen under en undersøkelse 
der du svelget en slange (gastroskopi)?
Ja Nei
4.12 I hvilken grad har du hatt følgende plager i 






Vekslende treg mage 
og diare.......................................................
Oppblåsthet ..........................................
Smerter i magen .......................
4.14 Til mannen: Har din partner noen gang 
spontanabortert?
Ja Nei Vet ikke












3 g per uke
Ferskvannsfi sk (ikke oppdrett) .........................................................................
Saltvannsfi sk (ikke oppdrett) ..............................................................................
Oppdrettsfi sk (laks, røye, ørret) .......................................................................
Tunfi sk (fersk eller hermetisert) ..........................................................................
Fiskepålegg ......................................................................................................................
Skjell ........................................................................................................................................
Krabbe (den brune innmaten) ..............................................................................
Hvalkjøtt/sel/kobbekjøtt .................................................................................
Innmat fra rein eller elg .....................................................................................
Innmat fra rype ...........................................................................................................
5.2 Hvor ofte spiser/spiste du vanligvis følgende? (antall ganger)
Som voksen I din barndom
Mølje (Antall ganger i året) .........................................................................................................................
Måsegg (Antall egg i året) ..........................................................................................................................
Reinsdyrskjøtt (Antall ganger i året) ..................................................................................................
5.3 Hvor mange ganger i måneden spiser du 
hermetiske matvarer (fra metallbokser)?
Antall ...........................................................................................




5.4 Bruker du vitaminer og/eller mineraltilskudd?




6.01 Driver du med følgende fritids- eller  yrkes-
aktiviteter: Bilreparasjoner/lakkering, keramikk-
arbeid, maling/lakkering/løsemidler, frisør, 
glassmester, elektriker
Antall timer per uke i gjennomsnitt .........
6.02 Om din tannstatus: Har du egne tenner? 
Ja Nei
6.03 Hvor mange amalgamfyllinger har du/har 
du hatt?
0 1-5 6-10 10+
6.04 Bruker du hårfargemidler?
Ja Nei
Hvis JA, hvor mange ganger per år? ..
6.05 Har du ufrivillig gått ned i vekt siste  6 
måneder?
Ja Nei
Hvis JA: Hvor mange kilo? ....................
6.07 Er du fornøyd med vekta di nå?
Ja Nei
6.06 Anslå din vekt da du var 25 år gammel:
Antall kg ........................................................








6.9 Har du eller andre noen gang blitt skadet på grunn av at du har 
drukket? .................................................................................................................................................................
Har en slektning, venn, lege, eller annet helsepersonell vært 








Ikke klart å stoppe og drikke alkohol når 
du først har begynt? .............................................................
Ikke klart å gjøre det som normalt 
forventes av deg fordi du har drukket? .........
Trengt en drink om morgenen for å få 
komme i gang etter en rangel? ..................................
Følt skyld eller anger etter at du har 
drukket? ..............................................................................................
Ikke klart å huske hva som skjedde kvelden 
før på grunn av at du hadde drukket? ............
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16.2 Hva slags hodepine er du plaget av?
Migrene Annen hodepine
16. HODEPINE
16.3 Omtrent hvor mange dager per måned har 
du hodepine?
Mindre enn 1 dag
1-6 dager 
7-14 dager
Mer enn 14 dager
16.1 Har du vært plaget av hodepine det siste året?
Ja Nei
Hvis NEI, gå til del 8, bruk av helsetjenester
16.4 Hvor sterk er hodepinen vanligvis?
Mild (hemmer ikke aktivitet)
Moderat (hemmer aktivitet)
Sterk (forhindrer aktivitet)
16.5 Hvor lenge varer hodepinen vanligvis?
Mindre enn 4 timer
4 timer – 1 døgn
1-3 døgn
Mer enn 3 døgn
16.7 Er hodepinen vanligvis: 




Ensidig smerte (høyre eller venstre) ..................
16.8 Før eller under hodepinen, kan du ha 
forbigående:
Ja Nei
Synsforstyrrelse? (takkede linjer, fl imring, 
tåkesun, lysglimt) ..................................................................
Nummenhet i halve ansiktet eller i 
handa? .......................................................................................
Forverring ved moderat fysisk aktivitet 
Kvalme og /eller oppkast .....................................
16.9 Angi hvor mange dager du har vært borte 
fra arbeid eller skole siste måned på grunn 
av hodepine: 
Antall dager ......................................................................
16.6 Dersom du er plaget av hodepine, når på året 






7. BRUK AV HELSETJENESTER
7.01 Har du noen gang opplevd at sykdom er blitt mangelfullt undersøkt eller behandlet, og at dette 
har gitt alvorlige følger?
Ja, det har rammet meg selv Ja, det har rammet en nær pårørende 
(barn, foreldre, ektefelle/samboer)
Nei
Hvis JA, hvor mener du årsaken ligger? (sett ett eller fl ere kryss):    
hos fastlege/allmennlege hos annet helsepersonell 
hos legevaktslege hos alternativ behandler
hos privatpraktiserende spesialist hos fl ere på grunn av svikt i rutiner og 
samarbeidhos sykehuslege
7.03 Har du noen gang klaget på behandling 
du har fått?
Har aldri vært aktuelt
Har vurdert å klage, men ikke gjort det
Har klaget muntlig
Har klaget skriftlig 
7.04 Hvor lenge har du hatt din nåværende 
fastlege/annen lege?
Mindre enn 6 mnd
6 til 12 mnd
12 til 24 mnd
Mer enn 2 år
7.02 Har du noen gang følt deg overtalt til å 
godta undersøkelse eller behandling som du 
selv ikke ønsket? 
Ja Nei
7.05 Har du en kronisk sykdom eller tilstand som 
påvirker din arbeidsevne eller dine daglige 
aktiviteter?
Ja Nei
Hvis JA, mener du dette har hatt uheldige 
helsemessige følger?
Ja Nei
7.06 Opplever du at fastlegen din har god nok 
forståelse for hvordan denne sykdommen eller 
tilstanden påvirker dine daglige aktiviteter?
Ja Nei Vet ikke
7.07 Snakket legen(e) til deg slik at du forsto dem? 
Svar på en skala fra 0 til 10, hvor 0=de var 
vanskelige å forstå og  10=de var alltid 
enkle å forstå
0 1 2 3 4 5 6 7 8 9 10
7.08 Hvordan vil du karakterisere behandlingen 
eller rådgivingen du fi kk siste gang du var 
hos lege? Svar på en skala fra 0 til 10,  hvor 
0= meget dårlig behandling og  10 = meget 
god behandling
0 1 2 3 4 5 6 7 8 9 10
7.09 Har du i løpet av de siste 12 mnd opplevd 
at det har vært vanskelig å bli henvist til 
spesielle undersøkelser (som røntgen eller 
liknende) eller til spesialisthelsetjenesten? 






7.10 Har du i løpet av de siste 12 mnd opplevd 
at det er vanskelig å bli henvist til fysio-







7.14 Har du i løpet av de siste 12 måneder brukt 
urtemedisin , naturmidler eller naturlegemidler?
Ja Nei
7.12 Har du i løpet av de siste 12 måneder vært til 
undersøkelse eller behandling i spesialist-
helsetjenesten?
Ja Nei
7.15 Har du i løpet av de siste 12 måneder brukt 
meditasjon, yoga, qi gong eller thai chi som 
egenbehandling?  
Ja Nei
7.16 Har du noen gang før 2001 gjennomgått 
en operasjon på sykehus eller spesialist-
klinikk?
Ja Nei
7.13 Hvordan vil du karakterisere erfaringen med 
spesialisten du sist møtte? Svar på en skala fra 
0 til 10, hvor 0 =meget dårlig erfaring og 
10=meget god erfaring
0 1 2 3 4 5 6 7 8 9 10
Hvis JA, snakket legen(e) til deg slik at du 
forstod dem? Svar på en skala fra 0 til 10, hvor 
0=de var vanskelige å forstå og 10=de var alltid 
enkle å forstå
0 1 2 3 4 5 6 7 8 9 10
7.11 Alt i alt, har du opplevd at det er vanskelig 









8. BRUK AV ANTIBIOTIKA
8.1 Har du brukt antibiotika i løpet av de siste 12 måneder? (all penicillinliknende medisin i form av 
tabletter, mikstur eller sprøyter)
Ja Nei Husker ikke
Kur 1 Kur 2 Kur 3 Kur 4 Kur 5 Kur 6
Hva fi kk du behandling mot? 
· Urinveisinfeksjon (blærebetennelse, blærekatarr) .........................
· Luftveisinfeksjon (øre-, bihule- hals- eller lungebetennelse) ...
· Annet .........................................................................................................................
Antall dagers antibiotika kur .......................................................................
Etter resept fra lege/tannlege ....................................................................
Uten kontakt med lege/uten resept:
· Kjøp direkte fra apotek i utlandet .............................................
· Kjøp gjennom Internett ........................................................................
· Rest fra tidligere kur til gjengelig hjemme ......................
· Fått av familie/venner ............................................................................
· Andre måter .......................................................................................................
8.2 Har du antibiotika hjemme nå?  
Ja Nei
8.3 Dersom du har antibiotika hjemme, vil du 
starte behandling uten å kontakte lege?
Ja Nei
Hvis JA, er dette etter avtale med lege/
tannlege?
Ja Nei
Hvis NEI, hvordan skaffet du deg dette 
legemiddelet?
Kjøp direkte fra apotek i utlandet .......................
Kjøp gjennom Internett ...................................................
Fått av familie/venner ......................................................
Andre måter .................................................................................
















Når jeg ikke kan velge fritt når jeg skal sove, da:
Går jeg til sengs klokken .....................................................................................................................................................................
Jeg gjør meg klar til å sove klokken .......................................................................................................................................
Antall minutter jeg trenger på å sovne ..................................................................................................................................................
Jeg våkner klokken ....................................................................................................................................................................................
Ved hjelp av: Vekkeklokke annen ytre påvirkning (støy, familie etc) av meg selv
Antall minutter jeg trenger på å stå opp ..............................................................................................................................................
Når jeg kan velge fritt når jeg skal sove, da:
Går jeg til sengs klokken .....................................................................................................................................................................
Jeg gjør meg klar til å sove klokken .......................................................................................................................................
Antall minutter jeg trenger på å sovne ..................................................................................................................................................
Jeg våkner klokken ....................................................................................................................................................................................
Ved hjelp av: Vekkeklokke annen ytre påvirkning ( støy, familie etc) av meg selv
Antall minutter jeg trenger på å stå opp ..............................................................................................................................................
9.1 Antall dager i løpet av uken hvor du ikke kan velge fritt når du vil sove (f.eks arbeidsdager)?
0 1 2 3 4 5 6 7
Vi vil spørre deg noen spørsmål som handler om dine søvnvaner når du ikke kan velge fritt når du 
må stå opp.
Vi vil spørre deg noen spørsmål som handler om dine søvnvaner når du kan velge fritt når du må 
stå opp.
9.2 De neste spørsmålene vil vi spørre deg om dine søvnvaner dår du fritt kan velge når du 
vil stå opp:
0 1 2 3 4 5 6 7
9.3 Har du hatt skiftarbeid de tre siste månedene?
Ja Nei
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10.7 Har du plager i form av tilbakevendende 
kviser/verkebyller, som er ømme/smertefulle 
og som ofte tilheler med arr, på noen av de 








Hvis JA: Hvor mange ganger i året fi kk du 
antibiotika i den perioden du var rammet?
1-2 3-4 Mer enn 4 ganger
10.5 Har du ofte eller bestandig noen av følgende 
plager? (sett ett kryss for hver linje)
Ja Nei
Hevelse i ankler og legger, særlig 
om kvelden .............................................................................
Eksem (rødt, kløende utslett) på 
leggene .......................................................................................
Smerter i beina når du går, men 
som forsvinner når du står stille .....................
10.6 Har du eller har du noen gang hatt følgende 
plager? (sett ett kryss for hver linje)
Ja Nei
Psoriasis? ...................................................................................
Atopisk eksem (barneeksem)? .........................
Tilbakevendende håndeksem? ........................
Tilbakevendende kviser over fl ere 
måneder? .................................................................................
Legg- eller fotsår som ikke ville gro i 
løpet av 3-4 uker?..........................................................
10. HUD OG HUDSYKDOMMER
10.2 Vasker du kroppen (inkludert armer og ben) 
med såpe når du dusjer eller bader? 
Ja Nei
Hvis JA på spørsmål om legg-og/eller fotsår, 
har du leggsår i dag?
Ja Nei
10.4 Har du noen gang fått antibiotikakur 
(penicillin og liknende medisin) på grunn 
av en hudlidelse, for eksempel betent 
eksem, kviser, leggsår som ikke vil gro, 
tilbakevendende verkebyll? 
Ja Nei
10.1 Hvor ofte dusjer eller bader du vanligvis? 
(sett ett kryss)
2 eller fl ere ganger daglig
1 gang daglig
4-6 ganger per uke
2-3 ganger per uke
1 gang per uke
sjeldnere enn en gang per uke
10.3 Hvor ofte vasker du vanligvis hendene dine 














Større kirurgisk inngrep med 
fjerning av hud .................................................................
Kirurgisk laserbehandling .....................................
10.8 Har du noen gang oppsøkt lege på grunn av 








11.2 Hvor lenge har du hatt disse smertene?
Antall år ............. måneder ............









11.3 Hvor ofte har du vanligvis disse smertene?
Hver dag En eller fl ere ganger i måneden
En eller fl ere ganger i uken Sjeldnere enn 1 gang i måneden
11.5 Hvilke former for behandling har du fått for smertene? (Kryss av for alle typer 
smertebehandling du har mottatt)
Ingen behandling Smerteskole/avspenning/psykoterapi
Smertestillende medisiner Akupunktur
Fysioterapi/kiropraktikk Alternativ behandling (homøopati, healing, 
aromaterapi, m.m.)Behandling ved smerteklinikk
Operasjon Annen behandling
Du svarte i det første spørreskjemaet at du har eller har hatt langvarige eller stadig tilbakevendende 
smerter i mer enn 3 måneder. Her er noen oppfølgingsspørsmål vi håper du vil svare på






0 1 2 3 4 5 6 7 8 9 10
Hvor sterke vil du si at smertene vanligvis er? ...............................





0 1 2 3 4 5 6 7 8 9 10





I hvor stor grad hindrer smertene deg i å utføre 
vanlige aktiviteter hjemme og i arbeid? .................................................
0 1 2 3 4 5 6 7 8 9 10
11. OPPFØLGINGSSPØRSMÅL KRONISK SMERTE 
10000
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11.6 Hva mener du er årsaken til smertene? (Kryss av for alle kjente årsaker)
Ulykke/akutt skade Fibromyalgi
Langvarig belastning Angina pectoris (hjertekrampe)





Leddgikt Annen årsak (beskriv under)






I det første spørreskjemaet svarte du at du har gjennomgått en operasjon i løpet av de siste tre 
årene. Nedenfor ber vi deg om å svare på noen spørsmål om den siste operasjonen du har 
gjennomgått.
12.1 Den siste operasjonen du gjennomgikk, hvor i kroppen ble du operert? (Dersom du samtidig 
ble operert fl ere steder i kroppen, settes fl ere kryss)
Siste operasjon












· Andre indre organer i magen .........................................................................................................................................










12.2 Bakgrunn for operasjonen:
Akutt sykdom/skade ..........................................................
Planlagt ikke kosmetisk operasjon ......................
Planlagt kosmetisk operasjon ...................................
12.3 Hvor ble du operert?
Universitetssykehuset i Nord-Norge (UNN) ..
Sykehuset i Harstad .............................................................
Annet offentlig sykehus ..................................................
Privat klinikk .................................................................................
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0 1 2 3 4 5 6 7 8 9 10
Hvor sterke smerter hadde du fra operasjonsstedet 
før operasjonen ..................................................................................................................
Hvor sterke smerter har du vanligvis fra 
operasjonsstedet nå ......................................................................................................
Hvor sterke smerter har du fra operasjonsstedet når 
smertene er på det sterkeste ...............................................................................
12.5 Hvor lenge er det siden du gjennomgikk 
operasjonen?
Antall år ............. måneder ............
12.6 Har du nedsatt følsomhet i et område nær 
operasjonsarret?
Ja Nei
12.7 Er du overfølsom for berøring, varme eller 
kulde i et område nær operasjonsarret? 
Ja Nei
12.8 Kan lett berøring av klær, dusj og lignende 
fremkalle ubehag/smerte? 
Ja Nei
12.9 Hvis du hadde smerter på operasjonsstedet 
før du ble operert, har du den samme type 
smerte nå? 
Ja Nei




17.6 Har du i løpet av de siste 12 måneder vært 
involvert i ulykke som krevde medisinsk 




17.2 Hvor lenge har du vært utsatt for kalde 
omgivelser under 0°C sist vinter?
Fritid/hobby (timer/uke) ..............................................
Arbeid (timer/uke) ..............................................................
Utendørs, godt kledd (timer/uke) .....................
Utendørs, tynnkledd (timer/uke) .......................
Innendørs, uten oppvarming (timer/uke) ...
I kalde omgivelser, med våte klær 
(timer/uke) ...................................................................................
Kontakt med kalde gjenstander/
verktøy (timer/uke) ............................................................
17. OPPFØLGINGSSPØRSMÅL ARBEID I KALDT KLIMA
I det første spørreskjemaet svarte du ja på at du arbeidet i kaldt klima. Her er noen oppfølgings-
spørsmål vi håper du vil svare på.




17.5 Har du opplevd kløe og/eller utslett i 
forbindelse med kulde?
Ja Nei
17.7 Opplever du noen av følgende symptomer 
mens du oppholder deg i kalde omgivelser? 
I så fall, ved hvilken temperatur oppstår 
symptomene?
Ja Nei Fra °C
Pusteproblemer .......................................
Pipende pust ...............................................
Slim fra lungene ......................................
Brystsmerter ................................................
Forstyrrelse i hjerterytmen ..........





Hvite fi ngre (kortvarig/
forbigående) ......................................................
Blå, blå-røde fi ngre (kortvarig/
forbigående) ......................................................






Kontroll av bevegelse (for eksempel skjelving) ..............................................................
Tungt fysisk arbeid...............................................................................................................................
Langvarig fysisk arbeid ...................................................................................................................
17.3 Hvilken omgivelsestemperatur 




Utføre andre aktiviteter utendørs .......
17.4 Har du hatt forfrysninger siste 12 måneder, 
med blemmer, sår eller skader i huden?
Ja Nei
Hvis JA, hvor mange ganger? .............
10000
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18. BRUK AV RESEPTFRIE SMERTESTILLENDE LEGEMIDLER
18.1 Paracetamol: (Pamol, Panodil, Paracet, 
Paracetamol, Pinex)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, pulver, stikkpiller) .......................
18.3 Ibuprofen: (Ibumetin, Ibuprofen, Ibuprox Ibux)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, pulver, stikkpiller) .......................
18.2 Acetylsalisylsyre: (Albyl-E,Aspirin,Dispril, Globoid)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, pulver, stikkpiller) .......................
18.4 Naproksen: (Naprosyn, Naproxen)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, pulver, stikkpiller) .......................






18.5 Fenazon med koffein: (Antineuralgica ,Fanalgin 
Fenazon-koffein, Fenazon-koffein sterke)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, pulver, stikkpiller) .......................
18.6 Diklofenak: (Otrifl u)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, pulver, stikkpiller) .......................
18.8 Kombiner du behandlingen med bruk av 
reseptbelagte smertestillende midler?
Ja Nei
18.7 Mener du å ha opplevd bivirkninger av noen 






Fenazon med koffein ...............................................
Diklofenak ............................................................................
I det første spørreskjemaet svarte du at du hadde brukt reseptfrie smertestillende legemidler de 




På side… i dette spørreskjemaet svarte du at du har eller hatt en hudsykdom. Her er noen 





19.1 Dersom du svarte ja på at du har hatt eller har psoriasis: 0 1 2 3 4 5 6 7 8 9 10
· Hvor mye plaget er du av din psoriasis i dag? ...................
· Hvordan vurderer du graden av din psoriasis når 
den er som verst? ................................................................................................
19.2 Dersom du svarte ja på at du har eller har hatt atopisk 
eksem:
· Hvor mye plaget er du av ditt atopiske 
eksem i dag? ......................................................................................................................
· Hvordan vurderer du graden av ditt atopiske 
eksem når det er som verst? ...................................................................
19.3 Dersom du svarte ja på at du har eller har hatt 
håndeksem:
· Hvor mye plaget er du av din håndeksem 
i dag? ..........................................................................................................................................
· Hvordan vurderer du graden av ditt håndeksem 
når det er som verst? .......................................................................................
19.4 Dersom du svarte ja på at du noen gang har vært 
plaget av tilbakekallende kviser:
· Hvor mye plaget er du av dine med kviser i dag? ..............
· Hvordan vurderer du graden av dine plager med 
kviser når det er som verst? .....................................................................
19.5 Dersom du svarte ja på at du har vært eller er plaget 
med verkebyller:
· Hvordan vurderer du plagene dine med 
verkebyller i dag? .................................................................................................
· Hvordan vurderer du graden av dine plager 
med verkebyller når det er som verst? ........................................
19.6 Hvor gammel var du da du fi kk verkebyller 
første gang?
0-12 år 26-35 år
13-19 år 36-50 år  
20-25 år 50+ år
19.8 Dersom du ikke lengre er plaget hvor 
gammel var du da plagene forsvant?
0-12 år 26-35 år
13-19 år 36-50 år  
20-25 år 50+ år
19.7 Her er en liste over faktorer som kan tenkes 
å utløse eller forverre verkebyller, kryss av 








ISM, Universitetet i Tromsø
9037 TROMSØ
telefon 77 64 62 07, telefaks 77 64 48 31
epost tromsous@ism.uit.no
